EP0812330A2 - Composes de peptidyl comprenant un motif structural itim regulant la fonction hematopoietique et leur utilisation - Google Patents

Composes de peptidyl comprenant un motif structural itim regulant la fonction hematopoietique et leur utilisation

Info

Publication number
EP0812330A2
EP0812330A2 EP96909494A EP96909494A EP0812330A2 EP 0812330 A2 EP0812330 A2 EP 0812330A2 EP 96909494 A EP96909494 A EP 96909494A EP 96909494 A EP96909494 A EP 96909494A EP 0812330 A2 EP0812330 A2 EP 0812330A2
Authority
EP
European Patent Office
Prior art keywords
itim
compound
cell
ptpic
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96909494A
Other languages
German (de)
English (en)
Inventor
John C. Cambier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Jewish Health
Original Assignee
National Jewish Center for Immunology and Respiratory Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Jewish Center for Immunology and Respiratory Medicine filed Critical National Jewish Center for Immunology and Respiratory Medicine
Publication of EP0812330A2 publication Critical patent/EP0812330A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to a product and process for regulating signal transduction pathways.
  • the invention provides for peptides and mimetics which regulate the responses of hematopoetic cells.
  • the present invention provides a product and process which regulates inflammatory and immune responses and further provides for the development of drug screening assays.
  • cell to cell communication coordinates the growth, differentiation and metabolism of the multitude of cell types contained in an organism. Communication between cells over long distances is facilitated by extracellular products (ligands) which act as signal molecules. Signal molecules travel through the organism to specific cells, where the signals induce a specific response only on those target cells that have receptors capable of binding those signal molecules. Binding of a signal molecule to a receptor initiates complex intracellular reactions within the cell bearing the receptor, triggering modifications of molecules present in the cell or altering patterns of gene expression, resulting in alteration of biological functions of the cell. This process is called signal transduction.
  • ligands extracellular products
  • Signal transduction pathways are used by cells to enable a cell to adjust to its environment.
  • a signal transduction pathway transmits signals received outside of a cell, across the cell's plasma membrane, through the cytoplasm of the cell and into the nucleus. Signals transmitted in this manner typically result in alteration of gene expression in the cell, though non-transcriptional events, such as certain changes in membrane structure and permeability, can also be regulated by intracellular signaling effected by the subject compositions.
  • Multiple cellular elements can be responsible for regulation of signal transduction in a cell. Such elements can include initiator molecules, transducer molecules, amplifier molecules, target molecules and second messenger molecules.
  • molecule includes proteins, lipids and ions (such as Ca + ).
  • Initiator molecules are capable of initiating signal transduction in a cell.
  • An example of an initiator molecule is an extracellular ligand capable of binding to a transducer molecule comprising a membrane-bound receptor on the surface of a cell.
  • Extracellular ligands can include, for example hormones, growth factors, antigens, differentiation agents, antibody molecules, histocompatibility molecules, mitogens, and other soluble or cell bound molecules.
  • a receptor/transducer molecule transmits a signal across the plasma membrane of a cell to intracellular amplifier molecules.
  • Transducer molecules can include any cell surface receptor having cytoplasmic regions capable of interacting with intracellular proteins involved in signal transduction.
  • Transducer molecules can include a catalytic domain or can recruit catalyticly active molecules to the receptor site, such as kinases or phosphatases.
  • Some examples of transducer molecules include, Fc receptors, T cell antigen receptors, B cell antigen receptors, major histocompatibility molecule (MHC) receptors, tyrosine kinase receptors, alpha and beta adrenergics, or other G protein-linked receptors, as well as cytokine receptors, growth factor receptors, CD22, CD19 and many others.
  • MHC major histocompatibility molecule
  • Receptors can be comprised of multiple proteins referred to as subunits, one category of which is referred to as a multisubunit receptor is a multisubunit immune recognition receptor (MIRR).
  • MIRRs include receptors having multiple noncovalently associated subunits and are capable of interacting with src-family tyrosine kinases.
  • MIRRs can include, but are not limited to, B cell antigen receptors (BCR), T cell antigen receptors (TCR), and Fc receptors.
  • BCR B cell antigen receptors
  • TCR T cell antigen receptors
  • Fc receptor MIRR include Fc ⁇ R and FcR ⁇ .
  • Other examples of receptor types include members of the Ig superfamily and lectin receptors.
  • a cell surface receptor may be functionally linked to an amplifier molecule by an adapter molecule. Eventually activation of the amplifier molecule results in the modulation of downstream effector molecules. Signal transduction often results in changes in gene transcription and leads to a change in the activation state of the
  • ITAM immunoreceptor tyrosine-based activation motif
  • Immune complexes consisting of antigen and IgG antibodies are known to be potent inhibitors of humoral immune responses that can lead to allergic responses (Chan et al., Immunology 21 :967-981, 1971 and Kohler et al., J. Immunol. 1 19:1979-1986, 1977). Immune complex mediated inhibition of antibody production has been shown to depend on the interaction between an IgG Fc receptor (Fc ⁇ RIIBl) and a B lymphocyte antigen receptor (BCR) on a B cell (Phillips et al., J. Immunol. 130:602-606, 1983).
  • Fc ⁇ RIIBl IgG Fc receptor
  • BCR B lymphocyte antigen receptor
  • Hematopoietic cells have a variety of functions including inflammatory and immune response functions. Many diseases involve cells derived from hematopoietic cell lineage including hyperimmune diseases, immune deficiency diseases, autoimmune diseases, cancer and allergic responses. Currently, therapies for treatment of abnormal inflammation or immune response can cause unwanted side effects.
  • the present invention relates to compositions and processes for regulating various hematopoietic cell functions.
  • the heretofore unappreciated and unrecognized interactions between particular molecules in certain signal transduction pathway of different hematopoetic cells has resulted in the elucidation of products and processes that permit regulation of cells, exemplary of which are the B cells, T cells, NK cells, basophils and mast cells.
  • the present invention permits regulation and treatment of various medical disorders including allergic responses, autoimmune diseases, inflammatory responses, immunodeficiency diseases, immunoproliferative diseases.
  • One aspect of the invention relates to a compound comprising an ITIM motif represented in the general formula: (I/V)X
  • Xi represents a Gly, Ala, Val, Ile.
  • X 2 represents a Gly, Ala, Val, Ile, Leu, Ser, Cys or Thr; and X 3 represents a Gly, Ala, Val, Ile, Leu, Ser, Cys, Thr, Met, Asn, Gin, Glu or Asp.
  • Xi represents a Val, Ile, Leu, Ser, Thr, Asp or His;
  • X 2 represents an Ala, Val, Ser or Thr; and
  • X3 represents a Leu, Ile, Thr, Met, Gin, Glu or Asp.
  • Exemplary ITIM motifs making up compounds of the present invention include VTYAQL. IVYTEL.
  • Y active site tyrosine
  • Y is represented by the general formula:
  • the ITIM motif is derived from naturally occurring amino acid residues.
  • the present invention also contemplates that all or only a portion of the ITIM motif can be a peptidomimetic.
  • all or a portion of peptide backbone of the ITIM motif can be derived as a peptidomimetic portion is selected from the group consisting of a retro-inverso peptidomimetic, a retro-enatio peptidomimetic, a trans-olefin peptidomimetic and a phosphonate peptidomimetic.
  • the ITIM motif is present in a peptidyl portion of the subject compound, which peptidyl portion has a molecular weight in the range of 750 daltons to 7500 daltons, though more preferably in the range of about 750 to 5000 daltons, and even more preferably in the range of about 750 to 2500 daltons.
  • Such molecular weights for any peptide will generally correspond to lengths of 6 to 60 amino acids, though peptides of 6, 7, 8, 9, 10, 1 1 , 12, 13, 15, and 20 amino acid residues are most preferred.
  • the ITIM motif is covalently linked by one or more peptide bonds (e.g., is part of a single polypeptide chain) to no more than 50 amino acid residues, in addition to the ITIM motif, which are identical to a polypeptide in which the ITIM motif naturally occurs, and more preferably no more than 40, 30 or 25 amino acid residues.
  • one or more peptide bonds e.g., is part of a single polypeptide chain
  • the ITIM motif is part of a fusion protein including a second amino acid sequence unrelated to a protein in which the ITIM motif naturally occurs.
  • compounds including an ITIM motif binds to SH2 domains of a signal transduction protein, e.g., such as a protein tyrosine phosphatase, ITIM- pl60 or ITIM-p70.
  • a signal transduction protein e.g., such as a protein tyrosine phosphatase, ITIM- pl60 or ITIM-p70.
  • the ITIM motif can bind to PTPIC and/or PTP1D.
  • the compound can modulate, e.g., inhibit or potentiate/activate, a signal transduction acitivity of the cellular component.
  • the ITIM compound regulates hematopoietic cell function by altering the enzymatic activity of an ITIM-binding protein, such as by altering the signal transduction pathway of an MIRR.
  • ITIM-binding proteins are proteins which bind the core ITIM peptide in a phosphotyrosine-dependent manner, such as by recognition of the phosphotyrosine by an SH2 domain.
  • the ITIM compound competitively inhibits binding of a PTPase, e.g., PTPIC or PTP1D, with a phosphorylated ITIM sequence the cytoplasmic domain of CD22, NKIRp58, Ly49 or Fc ⁇ receptors.
  • the ITIM compounds of the present invention are able to modulate second messenger generation in a hematopoetic cell, e.g., alter the phosphorylation of, for example, such signal transduction proteins as Zap70, p72syk, lyn, Vav, TCRz, FceR, Iga or Igb subunit of BCR; and/or increase (mobilize) intracellular free calcium from internal stores or the extracellular mileau.
  • an effective amount of an ITIM compound can reduce the extent of intracellular calcium mobilization resulting from B cell receptor cross-linking.
  • Another aspect of the present invention provides a pharmaceutical preparation comprising the ITIM compounds above in a physiologically acceptable carrier, and in a therapeutically-effective amount useful for modulating an intracellular signaling pathway in cells in of an animal being treating.
  • Still another aspect of the invention provides an ITIM mimetic which binds to an SH2 domain of PTPIC, activates the PTPIC phosphatase activity, and competitively inhibits binding of with an ITIM motif of any one or more of CD22, NKIRp58, Ly49 and Fc ⁇ receptors.
  • soluble peptide fragment of a negative regulatory receptor selected from the group consisting of CD22, NKIRp58, Ly49 and Fc ⁇ receptors (e.g., Fc ⁇ RI, Fc ⁇ RII, Fc ⁇ RIII), which peptide includes an ITIM motif.
  • the peptide has a molecular weight in the range of 750 to 7500 daltons; the peptide binds to an SH2 domain of PTPIC and allosterically regulates the tyrosine phosphatase activity of the PTPIC.
  • Yet another aspect of the present invention provides a method for modulating an an intracellular signaling pathway in a cell comprising altering an activity of an ITIM-binding protein involved in the intracellular signaling pathway by contacting the cell with a compound comprising an ITIM motif represented by the general formula:
  • the cell can be, for example, a B cell, a mast cell, a basophil, a T cell, and/ or a natural killer (NK) cell.
  • the cell can be treated ex vivo or in vivo.
  • the method is used to modulate immune responses, inflammatory responses, blood clotting initiation, release of histamine, destruction of virally infected cells, and/or destruction of infectious agents.
  • the subject method can be used to regulate the production and or release of molecules such antibodies, cytokines, chemokines, complement, prostglandins, leukotrienes and inflammatory mediators.
  • the subject method can used to treat or prevent such disease states as immunoproliferative diseases, immunodeficiency diseases, cancers, autoimmune diseases, infectious diseases and allergic responses.
  • the method protects an animal from a disease involving autoantibody production or involving IgE-induced basophil degranulation.
  • the method regulates hematopoietic cell function by inhibiting the activity of an MIRR, as for example by causing stimulation, e.g., ITIM- dependent acitivation, of the specific phosphatase activity of PTPIC.
  • stimulation e.g., ITIM- dependent acitivation
  • the present invention provides a method for regulating hematopoietic cell function by contacting a hematopoietic cell with an effective amount of a regulatory reagent capable of altering the activity of a regulatory molecule selected from the group consisting of PTPIC, PTP1D, ITIM-pl60 and ITIM-p70.
  • a regulatory reagent capable of altering the activity of a regulatory molecule selected from the group consisting of PTPIC, PTP1D, ITIM-pl60 and ITIM-p70.
  • regulatory molecules include ITIM mimetics as described herein, as well as general phosphotyrosine peptides such as pYXXL and pYXXV, and bispecific antibodies capable of crosslinking a stimulatory receptor protein with an inhibitory ITIM-containing receptor protein.
  • the method alters such hematopoietic cell function as selected from the group consisting of immunoproliferative diseases, immunodeficiency diseases, cancers, autoimmune diseases, infectious diseases and allergic responses.
  • the method can be used to regulate the production and/or release of molecules such as antibodies, cytokines, chemokines, complement, prostglandins, leukotrienes and inflammatory mediators.
  • the cell can be, for example, a B cell, a mast cell, a basophil, a T cell, and/ or a natural killer (NK) cell.
  • the cell can be treated ex vivo or in vivo.
  • the method can be used to protect an animal from a disease involving autoantibody production or involving IgE-induced basophil degranulation.
  • the subject method regulates hematopoietic cell function by inhibiting the activity of a MIRR, e.g., such as by stimulating the specific phosphatase activity of PTPIC or PTP ID.
  • a therapeutic composition of the present invention is useful for the treatment of any disease caused in part by abnormal signal transduction in a cell.
  • diseases include cancer, autoimmune disease, immunodeficiency diseases, immunoproliferative diseases, allergic responses, and inflammatory responses.
  • a therapeutic composition of the present invention is also useful in the regulation of an immune response during medical treatments, such as transplantation of organs or skin.
  • Autoimmune diseases can include, for example, systemic lupus, myasthenia gravis, rheumatoid arthritis, insulin dependent diabetes mellitus and experimental allergic encephalomyelitis.
  • Immunodeficiency diseases can include, for example, human AIDS, severe combined immunodeficiencies and hypogammaglobulinemia. Immunoproliferative diseases can include, for example, lymphomas and leukemias.
  • a therapeutic composition of the present invention is useful for the treatment of all forms of cancer, including tumor formation.
  • the present invention also makes available a method to identify agents, such as other ITIM mimetics, capable of altering a signal transduction activity of an SH2-containing protein, the method comprising: (a) forming a reaction mixture including (i) a compound, such as a peptide, comprising an ITIM motif, (ii) a target protein including at least one SH2 domain which specifically binds the ITIM motif by the SH2 domain, and (iii) a test agent; and (b) detecting interaction of the target protein with the ITIM motif, wherein a statistically significant change in the interaction of the target protein in the presence of the test agent, relative to the level of interaction in the absence of the test agent, indicates an activity of the test agent for altering an ITIM-dependent signal transduction activity of the SH2-containing target protein.
  • the target protein is a PTPase, such as PTPIC or PTP1D, or other ITIM-binding protein.
  • Detecting interaction of the target protein with the compound can be by a variety of formats, including measuring the level of enzymatic activity of the target protein, or detecting the direct interaction of the target protein with the compound.
  • the reaction mixture is a whole cell, and detecting interaction of the target protein with the compound comprises measuring the level of phosphorylation of one or cellular proteins.
  • the reaction mixture is a whole cell or cell lysate and detecting interaction of the target protein with the compound comprises measuring the level of intracellular calcium.
  • the reaction mixture is derived by recombinant expression of the compound in a cell.
  • the detection can comprise measuring one or more of (i) the level of phosphorylation of a cellular protein, (ii) the level of intracellular Ca 2+ , (iii) the level of a diacylglyceride, (iv) the level of an inositol phosphate, (v) the level of expression of an immediate early (cIE) gene product, such as myc, fos or jun.
  • cIE immediate early
  • the present invention also provides a method for identifying agents capable of altering the CD19-mediated signal transduction comprising:(a) forming a reaction mixture including (i) a PTPIC phosphatase, (ii) a phosphorylated CD 19 protein or PTPIC substrate derived therefrom, and (iii) a test agent; and (b) detecting interaction of PTPIC amd CD 19.
  • a reaction mixture including (i) a PTPIC phosphatase, (ii) a phosphorylated CD 19 protein or PTPIC substrate derived therefrom, and (iii) a test agent; and (b) detecting interaction of PTPIC amd CD 19.
  • kits for performing such drug screening assays comprising a PTPIC or PTP1D phosphatase, an ITIM mimetic capable of binding and activating the PTP, a PTP substrate, and a putative regulatory compound.
  • Still another aspect of the present invention provides a method to identify a treatment for abnormal hematopoietic cell function, comprising: (a) isolating basophils from a patient; (b) contacting the basophils with a ligand selected from the group consisting of Fab' IgG antibody and whole IgG antibody; and (c) diagnosing abnormal hematopoietic cell function by determining PTPIC activity in the basophils after the step of contacting with the ligand.
  • Figure 1 shows the sequence alignment between inhibitory receptors.
  • GenBank accession numbers for the sequences used in this paper are: human p58.183: U24074, human p58.EB6: U24075, human p70: L41269, mouse Ly49A: M25812, mouse Ly49C: U10304, mouse Ly49G4: U10093, human CD22b: X59350, mouse CD22b: L16928, human FcgRIIBl : M31935, mouse FcgRIIBl : M17515, NKG2A: X54867. Amino-acid numbers corresponding to the stretches are indicated.
  • FIG. 2 shows inhibition of BCR mediated Ca2+ mobilization by the PI 3-kinase inhibitor Wortmannin.
  • Ca ⁇ mobilization in A20 cells stimulated with intact ( ) rabbit anti-mouse Ig antibody, or F(ab')2 fragments in the presence ( ) or absence ( — ) of 1 OnM
  • Wortmannin A20 cells were loaded with Indo-1 AM (Molecular Probes) and subsequently stimulated with either F(ab')2 (12 ⁇ g/ml) or intact (20 ⁇ g/ml) rabbit anti-mlg, and [Ca ⁇ +jj was monitored with a flow cytometer for 15 min (model 50H, Ortho Diagnostic Systems). The mean [Ca ⁇ +jj (panel A) and percent of cells that responded (panel B) was evaluated with an appended data acquisition system and the MultiTIME software (Phoenix Flow Systems). Figure 3 shows that CD 19 is required for prolonged BCR mediated Ca2+ mobilization.
  • the signal transduction pathways engaged upon receptor-ligand interaction represent the key mechanism by which cellular responses are controlled.
  • the signals transduced by cell surface receptors may be either stimulatory or inhibitory depending upon the intracellular cascade of events which is initiated.
  • the present invention provides for agents which are useful in the modulation, e.g. either to potentiate or inhibit the activation of hematopoetic cells by altering the balance of stimulatory and inhibitory signal transduction.
  • the present invention also relates to the development of drug screening assays useful in the identification of other cell regulatory compounds.
  • various aspects of the present invention derive from the elucidation of certain mechanisms by which signal transduction from MIRRs and the like are down regulated.
  • coligation of the Fc receptor on B cells e.g., Fc ⁇ RIIB1
  • BCR B cell antigen receptor
  • PTPIC is an effector of BCR-Fc ⁇ RIIBl negative signal cooperation and represents a potential therapeutic target for up- or down-regulation of humoral immune responses both in vitro and in vivo.
  • NK natural killer
  • ITIM sequence(s) present in the NK MHC class I protein receptors NKIR
  • the effector functions initiated by stimulation of the CD3/TCR complex are also demonstrated to be inhibited by a PTP1C/1D- dependent mechanism. Accordingly, recruitment of and or activation of specific phosphatases by ITIM sequences is apparently a mechanism shared by several different pathways as a means for downregulating receptor function with.
  • the core peptide sequence of the ITIM which is critical to activation of PTPIC and PTP ID is also disclosed.
  • the optimal sequence for PTPIC activation contrary to the general teachings in the art concerning SH2 domain specificity, requires amino acid residues both C- terminal and N-terminal to the phosphotyrosine.
  • Still other aspects of the present invention derive from the discovery of novel interactions beyond the ITIM/PTP interactions.
  • the appended examples describe that the BCR co-receptor CD 19 is an apparent substrate for PTPIC.
  • Dephosphorylation of CD 19 by Fc ⁇ R-activated PTPIC leads to diminished association of CD19 with PI-3K and subsequent failure of BCR-mediated Ca 2+ mobilization.
  • the dephosphorylation reaction of CD 19 by PTPIC is another potential therapeutic target for developing agents which modulate B cell activation and/or inhibition.
  • ITIM pi 60 and ITIM p70 interactions are described below. Like PTPIC, each of these proteins demonstrate binding to phosphorylated ITIM peptides indicating the presence of an ITIM-binding motif.
  • a regulatory reagent can regulate cell function by, for example: altering the interaction between a signal transduction molecule and an amplifier, or target molecule; altering the binding between the signal transduction molecule and its target molecule; altering the enzymatic activity of a signal transduction molecule, or by modulating the phosphorylation of the signal transduction or other target molecule.
  • altering the binding can refer to altering the affinity of one molecule for another, blocking the sites of binding between two molecules, or interfering with the delivery of a molecule to the area of another molecule or allosterically altering a molecule so that it has either enhanced or diminished binding abilities.
  • modulation of signal transduction pathways is meant to include either agonistic or antagonistic effects on cellular activation. As would be understood by one of skill in the art, any alteration in a signal transduction pathway would be indicated by a statistically significant change in an assay result in the presence of a putative regulatory compound relative to a result obtained in the absence of the compound.
  • the compounds of the present invention and compositions in which they are employed are particularly advantageous in that they are useful for regulating a wide variety of cellular functions by regulating different stages of signal transduction in a cell.
  • the subject compounds can be employed to effect such cellular events as proliferation, differentiation and cell death, as well as secretion and metabolic (both anabolic and catabolic) activities, in both cell culture and in vivo therapies.
  • another aspect of the invention provides for methods to identify additional compounds capable of regulating signal transduction in a cell.
  • hematopoietic cells include erythrocytes (red blood cell) and leukocytes (white blood cell).
  • Leukocytes include neutrophils (i.e., polymorphonuclear leukocytes), basophils, eosinophils, mast cells, megakaryocytes, monocytes, lymphocytes, natural killer (NK) cells and macrophages.
  • neutrophils i.e., polymorphonuclear leukocytes
  • basophils i.e., polymorphonuclear leukocytes
  • eosinophils i.e., monocytes
  • lymphocytes i.e., monocytes
  • lymphocytes i.e., monocytes
  • T lymphocytes T lymphocytes
  • the use of the subject compounds is capable of regulating red blood cell growth and or differentiation.
  • the peptides of the present invention include the general or core amino acid motif (hereinafter "ITIM" motif) represented by the general formula (I/V)XYXX(L V), in which each of I represents isoleucine or a mimetope thereof, V represents a valine or a mimetope thereof, each X independently represents any amino acid or mimetope thereof, Y represents a tyrosine, a phosphotyrosine or a mimetope thereof, and L represents a leucine or mimetope thereof.
  • the tyrosine residue is phosphorylated.
  • an isolated ITIM motif is sufficient, e.g., contains the necessary structural information, for modulating a variety of signal transduction processes involving hematopoetic receptors.
  • the subject ITIM peptide comprises an ITIM sequence represented by (V/I)XYXX(V/L) such as VTYAQL, IVYTEL, VTYTQL, IVYTEL, VTYAQL, ILYTEL, VTYSMV, VTYTTL, VTYSTV, VIYSDL, or ITYAEL, wherein each V represents a valine or mimetope thereof.
  • T represents a threonine or mimetope thereof
  • Y represents a phosphotyrosine or mimetope thereof
  • A represents an alanine or mimetope thereof
  • Q represents a glutamine or mimetope thereof
  • L represents a leucine or mimetope thereof
  • I represents an isoleucine or mimetope thereof
  • E represents a glutamic acid or mimetope thereof
  • S represents a serine or mimetope thereof
  • M represents a methionine or mimetope thereof
  • D represents an aspartic acid or mimetope thereof.
  • the tyrosine residue is phosphorylated.
  • ITIM peptides comprise an ITIM sequence represented by one of EQDPQEVTYAQLN, TPPTDIIVYTELP, EQDPQEVTYTQLN, TPPTDIIVYTELP, EQDPEEVTYAQLD, TPPTDTILYTELP, MSEQEVTYSMVRF, MSEQEVTYTTLRF, MSEQEVTYSTVRF, or
  • ITIM peptides are derived from NKIRp58 or Ly49.
  • the tyrosine residue is phosphorylated.
  • the subject ITIM peptide includes a core ITIM sequence represented in the general formula IXYXXL, as for example ITYSLL.
  • Preferred ITIM peptides are represented by either of TAENTITYSLLKH or GAENTITYSLLMH, in which each E represents a glutamic acid or mimetope thereof, G represents glycine or a mimetope thereof, A represents alanine or a mimitope thereof, N represents asparagine or a mimetope thereof, each T represents threonine or a mimetope thereof, I represents isoleucine or a mimetope thereof, Y represents tyrosine or phosphotyrosine or a mimetope thereof, S represents serine or a mimetope thereof, each L represents leucine or a mimetope thereof, K represents lysine or a mimetope thereof, M represents methionine or a mimetope thereof, and H represents histidine or a mime
  • ITIM peptides are derived from Fc receptor sequences, and more preferably B cell Fc receptors.
  • Preferred ITIM peptides are derived from an Fc ⁇ RII and more preferably from an Fc ⁇ RIIBl.
  • the tyrosine residue of the ITIM motif is phosphorylated, or is a phosphotyrosine analog, e.g. as described below. Although forms in which the tyrosine residue is not phosphorylated are also contemplated.
  • ITIM agonists and ITIM antagonists are molecules which are able to mimic or inhibit, respectively, the transduction of a signal by an ITIM sequence occurring in a cellular protein.
  • ITIM mimetics e.g., "ITIM mimetics” or “mimetopes”
  • the agonism or antagonism of an ITIM-dependent signal can arise from, for example, the ITIM mimetic allosterically activating an ITIM- binding protein, e.g., altering its enzymatic and/or binding specificity profile, or by competively inhibiting the binding of an ITIM-binding protein with a naturally occurring ITIM sequence.
  • An ITIM mimetic is bioactive if it is capable of regulating the production of antibodies, cytokines, chemokines, complement, prostglandins, leukotrienes and other inflammatory mediators by a cell involved in inflammatory and immune responses.
  • ITIM mimetics of the present invention are capable, through modulating signal transduction, of ultimately regulating the phosphorylation of intracellular substrates, the production of second messenger molecules, and the activation of gene transcription.
  • Target molecules can include, but are not limited to, phosphatidylinositol 3-kinase (PI-3K), Grb 2, sos, P21 rasGAPase-activating protein and associated PI 90 and P62 protein, phospholipases such as PLC ⁇ l and PLC ⁇ 2, She, and the MAP kinases, including the Janus (JAK) family of kinases.
  • the compound of the present invention is capable of modulating the phosphorylation of the z chain of the TCR, Iga or Igb subunits of the BCR, Zap 70, p72syk, Lyn, or Vav.
  • ITIM mimetics of the present invention can be used to modulate the production of such natural products as C5a, interleukin-8 (IL-8), monocyte chemotactic protein lot (MlPl ⁇ ), monocyte chemotactic protein l ⁇ (MlPl ⁇ ), monocyte chemoattractant protein 1 (MCP-1), monocyte chemoattractant protein 3 (MCP-3), platelet activating factor (PAF), N-Formyl-methionyl-leucyl-[3H]phenylalanine (FMLP), leukotriene B4 (LTB4), LTC4, gastrin releasing peptide (GRP), RANTES, eotaxin, lymphotactin, IP10, 1-309
  • the subject ITIM mimetics are capable of competing with the cytoplasmic domains of a cell surface receptor for the binding of protein tyrosine phosphatases.
  • mimetics are capable of competing for the binding of an SH2 containing protein tyrosine phosphatase (PTP) with a portion of the cytoplasmic domain of a receptor, such as one of the group of Fc ⁇ R, natural killer cell receptor for MHC class I (for example, NKIRp58 or Ly 49), CD22, IL2 ⁇ R, IL-3 ⁇ R, EPOR, and c-kit.
  • PTP protein tyrosine phosphatase
  • the peptides of the present invention are capable of competing for the binding of an SH2 containing PTP with a portion of the cytoplasmic domain of an Fc ⁇ R or Ly 49 or NKIRp58R.
  • the subject peptides are capable of competing for the binding of an SH2 containing PTP with a portion of the cytoplasmic domain of an Fc ⁇ RI, Fc ⁇ RII, Fc ⁇ RIII, Ly49, or NKIRp58R, more preferably with Fc ⁇ RIIBl
  • the PTP is one of PTPIC or PTP ID.
  • the subject ITIM peptides are encoded by a nucleic acid which hybridizes under stringent conditions with a nucleic acid encoding an ITIM portion of the cytoplasmic domain of an Fc ⁇ R, MHC class I R, CD22, IL2 ⁇ R, IL3 ⁇ R, or EPOR.
  • nucleic acids encoding the subject peptides are capable of specifically hybridizing to a nucleic acid comprising the ITIM portion of the cytoplasmic domain of an Fc ⁇ RI, Fc ⁇ RII, Fc ⁇ RIII, Ly49, or NKIRp58R, more preferably with Fc ⁇ RIIBl .
  • ITIM mimetics of the present invention are capable of modulating the interaction of a PTP with CD 19, resulting in changes in the phosphorylation pattern of CD 19.
  • a phosphatase e.g. PTPIC or PTP ID
  • the subject compounds lead to the dephosphorylation of tyr 484 and/or 515 on CD 19.
  • an ITIM mimetic leads to a modulation in the activation of PI3 kinase.
  • an ITIM mimetic is capable of modulating the activation of PLC ⁇ .
  • the subject mimetics lead to a modulation in intracellular second messenger generation, for example Ca 2+ influx from outside the cell, by causing a inhibiting the interaction of CD 19 with PI3kinase activity.
  • a subject ITIM peptide is capable of modulating second messenger generation by modulating the production of IP3 and thus the release of Ca 2+ from intracellular stores.
  • an ITIM mimetics of the present invention is capable of modulating the activity of Grb2 or sos, preferably by binding to an SH2 containing PTP.
  • an ITIM binding molecule is capable of binding, via a phosphotyrosine residue to an ITIM peptide or mimetic.
  • an ITIM peptide or mimetic binds to SH2 domains.
  • an ITIM mimetic binds an SH2 containing tyrosine phosphatase in a manner such that the peptide is capable of regulating the activity of the phosphatase.
  • an ITIM peptide activates a PTP.
  • an ITIM mimetic is of a size and nature that enables the compound to be bound by the carboxy terminal SH2 domain of a PTP.
  • PTP ID, pi 60, or p70 are ITIM binding molecules.
  • an ITIM mimetic of the present invention binds to and regulates the activity of a PTP present in hematopoetic cells, for example PTPIC or PTP ID.
  • the mimetics of the present invention bind to PTPIC or PTP ID SH2 domain resulting in its regulation of phosphatase activity by an allosteric mechanism.
  • an ITIM of the present invention binds to the carboxy terminal SH2 domains resulting in an increase in the phosphatase activity of the enzyme.
  • Such a modulation in phosphatase activity may be measured using any number of techniques, including measuring changes in the level of phosphorylation of a known natural or synthetic substrate, such as phosphorylated lyn peptide as described in the appended Examples.
  • an ITIM peptide of the present invention is capable of stimulating the specific activity of PTPIC.
  • the term "specific activity" refers to the rate at which a PTPIC molecule can dephosphorylate a phosphorylated substrate molecule, such as phosphorylated CD19, Syk, Lyn, Fyn or PI-3 kinase. The rate of specific activity can be measured by, for example, the rate at which PTPIC dephosphorylates a phosphorylated substrate molecule.
  • an ITIM peptide of the present invention is capable of stimulating the specific activity of PTPIC between about 2-fold and about 10-fold, and more preferably about 5-fold. Stimulation of specific activity is seen when the peptide is incubated with PTPIC in the presence of phosphorylated Fyn peptide as described in detail in Example 5.
  • a regulatory reagent of the present invention regulates hematopoietic cell function by altering the enzymatic activity of a signal transduction molecule, preferably by stimulating the enzymatic activity of a signal transduction molecule.
  • a regulatory reagent of the present invention regulates hematopoietic cell function by modulating the activity of an activating receptor including an MIRR, a lectin receptor, or an Ig superfamily receptor.
  • the subject ITIMs regulate signaling via the BCR, TCR,Fc ⁇ R, a cytokine receptor, or CD 16.
  • a peptide of the present invention modulates the signals transduced by one of these receptors by modulating a signal transduced via an inhibitory receptor, such as, CD22, Fc ⁇ RI, Fc ⁇ RIII, NKlRp58, Ly49, IL2Rb, IL3Rb, EPOR, or c-kit.
  • an inhibitory receptor such as, CD22, Fc ⁇ RI, Fc ⁇ RIII, NKlRp58, Ly49, IL2Rb, IL3Rb, EPOR, or c-kit.
  • a peptide of the present invention inhibits via a CD22, Fc ⁇ RIII, NKlRp58, Ly49, IL2Rb, IL3Rb, EPOR, or c-kit, molecule.
  • One embodiment of the present invention includes a regulatory reagent that is capable of regulating the activity of one or more of the signal transduction molecules phosphotyrosine phosphatase IC (PTPIC), PTP ID, ITIM-pl60 and/or ITIM-p70, in a cell.
  • Suitable methods for regulating PTPIC, PTP ID, ITIM-pl60 and/or ITIM-p70 activity in a cell include altering the enzymatic activity of the molecule; altering the binding ability of the molecule to its substrate; altering the concentration of the molecule in a cell; and/or phosphorylating the molecule.
  • a subject ITIM is capable of modulating the binding of a PTP to its substrate.
  • an ITIM modulates the binding of ITIM pi 60 or ITIMp70 to upstream or downstream elements in a signaling cascade.
  • an ITIM peptide competes for the binding of ITIM pi 60 or p70 with the cytoplasmic domain of a negative regulatory receptor, such as CD22, Fc ⁇ R, or MHC class I R.
  • One embodiment of the present invention pertains to a composition that is capable of altering the enzymatic activity of a PTP.
  • reagents include compounds that are capable of binding to a src homology region of a PTP, preferably a src homology region 2 (SH2) region of PTP, and more preferably a carboxyl SH2 domain of a PTP.
  • a peptide of the present invention binds to the catalytic region of a PTP.
  • the PTP is at least one of PTPIC or PTP ID.
  • Another embodiment includes a regulatory reagent that is capable of altering the binding ability of a PTP to its substrate.
  • the PTP is at least one of PTPIC or PTP ID.
  • such reagents include compounds that are capable of binding to an SH2 domain and or catalytic domain of a PTP, or phosphotyrosine sites of a substrate of PTP, such as the tyrosine autophosphorylation site on an ITAM region of an MIRR.
  • a preferred tyrosine autophosphorylation site is residue 394 of pITAM of the Ig ⁇ and Ig ⁇ subunits of the B cell receptor.
  • such reagents are capable of binding to phosphotyrosines 484 and/or 515 of CD 19. The ability of a subject peptide to modulate the binding of a PTP to other substrates is also contemplated.
  • Another embodiment of the present invention includes a regulatory reagent, or mimetope thereof, that is capable of altering the concentration of PTPIC in a cell.
  • a regulatory reagent or mimetope thereof, that is capable of altering the concentration of PTPIC in a cell.
  • such reagents include PTPIC protein or a nucleic acid molecule encoding PTPIC (described in detail below).
  • Another embodiment of the present invention includes a regulatory reagent, or mimetope thereof, that is capable of altering the activity of ITIM-p70 in a cell.
  • a regulatory reagent or mimetope thereof, that is capable of altering the activity of ITIM-p70 in a cell.
  • such reagents include compounds capable of binding to a portion of ITIM-p70 (see appended Examples) such that the enzymatic or substrate binding activity of the protein is altered.
  • compounds capable of increasing the concentration of ITIM-p70 in a cell such as a protein or a nucleic acid molecule encoding for ITIM-p70 protein.
  • an isolated, or biologically pure peptide is a peptide that has been removed from its natural milieu.
  • isolated and biologically pure do not necessarily reflect the extent to which the protein has been purified.
  • An isolated ITIM containing peptide can be obtained from a natural source, e.g., isolated peptide from a full-length protein, produced using recombinant DNA technology, or chemical synthesis as is well known in the art.
  • the peptide can be substituted and/or derivatized, e.g., acetylated, glycosylated, carboxymethylated anchored by myristoylated, prenylated or palmitoylated amino acids.
  • an isolated ITIM peptide that has an amino acid sequence that enables the peptide to be bound by PTPIC, PTPID, ITIM-pl60 and/or ITIM-p70.
  • An ITIM peptide of the present invention is of a size that enables the peptide to be bound by at least one binding site of PTPIC, PTPID, ITIM-pl60 and or ITIM-p70, preferably, at least about 4 amino acid residues, more preferably at least about 5 amino acid residues, and even more preferably at least about 6 amino acid residues.
  • an ITIM peptide of the present invention has a size of about 13 amino acid residues.
  • an ITIM peptide of the present invention is capable of being bound by an SH2 domain PTPIC.
  • an ITIM peptide of the present invention is capable of being bound by a carboxyl SH2 domain of PTPIC.
  • the peptidyl component of the subject compounds includes, in addition to the ITIM, no more than about 25 amino acid residues of a protein in which an ITIM motif exists, more preferably no more than 10-15, and even more preferably 6 or less.
  • a preferred composition includes a peptide comprising ITIM- motif and having a molecular weight in the range of about 750 to 7500 daltons, more preferably from about 1000 to 5000 daltons, and even more preferably in the range of about 1000 to 2500 daltons.
  • a “mimetope” refers to any compound that is able to mimic the ability of an isolated compound of the present invention.
  • the term “peptide”, with reference to ITIM motifs, will be understood to also include mimetopes.
  • a mimetope can be a peptide that has been modified to decrease its susceptibility to degradation but that still retains regulatory activity.
  • Other examples of mimetopes include, but are not limited to, protein-based compounds, carbohydrate-based compounds, lipid-based compounds, nucleic acid-based compounds, natural organic compounds, synthetically derived organic compounds, anti-idiotypic antibodies and/or catalytic antibodies, or fragments thereof.
  • a mimetope can be obtained by, for example, screening libraries of natural and synthetic compounds for compounds capable of regulating the activity of a tyrosine kinase as disclosed herein.
  • a mimetope can also be obtained, for example, from libraries of natural and synthetic compounds, in particular, chemical or combinatorial libraries (i.e., libraries of compounds that differ in sequence or size but that have the same building blocks).
  • a mimetope can also be obtained by, for example, rational drug design. In a rational drug design procedure, the three-dimensional structure of a compound of the present invention can be analyzed by, for example, nuclear magnetic resonance (NMR) or x-ray crystallography.
  • NMR nuclear magnetic resonance
  • x-ray crystallography x-ray crystallography
  • the three-dimensional structure can then be used to predict structures of potential mimetopes by, for example, computer modelling, the predicted mimetope structures can then be produced by, for example, chemical synthesis, recombinant DNA technology, or by isolating a mimetope from a natural source (e.g., plants, animals, bacteria and fungi).
  • a natural source e.g., plants, animals, bacteria and fungi.
  • amino acid residue and “peptide residue” it is meant an amino acid or peptide molecule without the -OH of its carboxyl group (C-terminally linked) or the proton of its amino group (N-terminally linked).
  • carboxyl group C-terminally linked
  • N-terminally linked N-terminally linked
  • the abbreviations used herein for designating the amino acids and the protective groups are based on recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (see Biochemistry (1972) 1 1 :1726- 1732). For instance Met, Ile, Leu, Ala and Gly represent "residues" of methionine, isoleucine, leucine, alanine and glycine, respectively.
  • amino acid side chain is that part of an amino acid exclusive of the -CH(NH 2 )COOH portion, as defined by K. D. Kopple, "Peptides and Amino Acids”. W. A.
  • side chains of the common amino acids are -CH 2 CH 2 SCH 3 (the side chain of methionine), -CH 2 (CH 3 )-CH 2 CH 3 (the side chain of isoleucine), -CH 2 CH(CH 3 ) 2 (the side chain of leucine) or H-(the side chain of glycine).
  • amino acids used in the application of this invention are those naturally occurring amino acids found in proteins, or the naturally occurring anabolic or catabolic products of such amino acids which contain amino and carboxyl groups.
  • Particularly suitable amino acid side chains include side chains selected from those of the following amino acids: glycine, alanine, valine, cysteine, leucine, isoleucine, serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine, lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan.
  • amino acid residue further includes analogs, derivatives and congeners of any specific amino acid referred to herein.
  • the present invention contemplates the use of amino acid analogs wherein a side chain is lengthened or shortened while still providing a carboxyl, amino or other reactive precursor functional group for cyclization, as well as amino acid analogs having variant side chains with appropriate functional groups).
  • the subject peptidomimetic can include an amino acid analog as for example, b-cyanoalanine, canavanine, djenkolic acid, norleucine, 3 -phosphoserine, homoserine, 1-methylhistidine, dihydroxyphenylalanine, 5-hydroxy-tryptophan, or 3-methylhistidine.
  • amino acid analog as for example, b-cyanoalanine, canavanine, djenkolic acid, norleucine, 3 -phosphoserine, homoserine, 1-methylhistidine, dihydroxyphenylalanine, 5-hydroxy-tryptophan, or 3-methylhistidine.
  • Other naturally occurring amino acid metabolites or precursors having side chains which are suitable herein will be recognized by those skilled in the art and are included in the scope of the present invention.
  • D and L stereoisomers of such amino acids when the structure of the amino acid admits of stereoisomeric forms.
  • the configuration of the amino acids and amino acid residues herein are designated by the appropriate symbols D, L or DL, furthermore when the configuration is not designated the amino acid or residue can have the configuration D, L or DL.
  • D, L or DL the structure of some of the compounds of this invention includes asymmetric carbon atoms.
  • isomers arising from such asymmetry are included within the scope of this invention.
  • Such isomers are obtained in substantially pure form by classical separation techniques and by sterically controlled synthesis.
  • a named amino acid shall be construed to include both the D or L stereoisomers, though it will be understood that the amino acid is preferably the L stereoisomer.
  • mimetopes can include analogs of the phosphotyrosine.
  • a phosphotyrosine moiety, pTyr can be represented by the general formula
  • X is absent or represents O, S, or N
  • D represents O or S
  • D 2 represents N 3 , SH 2 , NH 2 , or NO 2
  • Rj and R 2 each independently represent hydrogen, a lower alkyl, or a pharmaceutically acceptable salt, or Rj and R 2 taken together with the O-P-O, O-V-O or O-As-O atoms to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure.
  • the ⁇ r ⁇ -substituted phenylalanine is the most preferred. In many embodiments, it will be desirable that the phosphoTyrosine be a non-hydrolyzable phosphotyrosine analog. In a preferred embodiment, the phosphotyrosine is phosphonodifluoromethyl phenylalanine (F 2 Pmp).
  • mimetopes of the subject ITIM peptides can be provided as non-hydrolyzable peptide analogs.
  • peptide analogs of the present invention can be generated using, for example, benzodiazepines (e.g., see Freidinger et al. in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gama lactam rings (Garvey et al. in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988, pl23), C-7 mimics (Huffman et al.
  • the peptidomimetic can be derived as a retro-inverso analog of the peptide.
  • the TITYSLL peptide can be generated as the retro- inverso analog:
  • retro-inverso analogs can be made according to the methods known in the art, such as that described by the Sisto et al. U.S. Patent 4,522,752.
  • the illustrated retro-inverso analog can be generated as follows.
  • the geminal diamine corresponding to the N-terminal threonine is synthesized by treating a protected threonine analog with ammonia under HOBT-DCC coupling conditions to yield the N-Boc amide, and then effecting a Hofmann-type rearrangement with I,I-bis-(trifluoroacetoxy)iodobenzene (TIB), as described in Radhakrishna et al. (1979) J. Org. Chem. 44:1746.
  • TIB I,I-bis-(trifluoroacetoxy)iodobenzene
  • the product amine salt is then coupled to a side-chain protected (e.g., as the benzyl ester) N-Fmoc D-Ile residue under standard conditions to yield the pseudodipeptide.
  • the Fmoc (fluorenylmethoxycarbonyl) group is removed with piperidine in dimethylformamide, and the resulting amine is trimethylsilylated with bistrimethylsilylacetamide (BSA) before condensation with suitably alkylated, side- chain protected derivative of Meldrum's acid, as described in U.S. Patent 5,061,81 1 to Pinori et al., to yield the retro-inverso tripeptide analog.
  • BSA bistrimethylsilylacetamide
  • the pseudotripeptide is then coupled with with an L-phosphotyrosine analog under standard conditions to give the protected tetrapeptide analog.
  • the protecting groups are removed to release the product, and the steps repeated to enlogate the tetrapeptide to the full length peptide.
  • a mixed peptide e.g. including some normal peptide linkages, can be generated.
  • sites which are most susceptible to proteolysis are typically altered, with less susceptible amide linkages being optional for mimetic switching
  • the final product, or intermediates thereof, can be purified by HPLC.
  • the peptidomimetic can be derived as a retro- enatio analog of the peptide, such as the exemplary retro-enatio peptide analog derived for the illustrative TITYSSL peptide:
  • Retro-enantio analogs such as this can be synthesized using D-enatiomers of tyrosine or phosphotyrosine analogs and commercially available D-amino acids and standard solid- or solution-phase peptide-synthesis techniques.
  • a suitably amino-protected (t-butyloxycarbonyl, Boc) D-threonine residue (or analog thereof) is covalently bound to a solid support such as chloromethyl resin.
  • the resin is washed with dichloromethane (DCM), and the BOC protecting group removed by treatment with TFA in DCM.
  • the resin is washed and neutralized, and the next Boc- protected D-amino acid (D-Ile) is introduced by coupling with diisopropylcarbodiimide.
  • the resin is again washed, and the cycle repeated for each of the remaining amino acids in turn (D-Thr, D-pTyr, etc).
  • the protecting groups are removed and the peptide cleaved from the solid support by treatment with hydrofluoric acid anisole/dimethyl sulfide/thioanisole.
  • the final product is purified by HPLC to yield the pure retro-enantio analog.
  • trans-olefin derivatives can be made for the subject polypeptide.
  • an exemplary olefin analog is derived for the illustrative TITYSSL peptide:
  • trans olefin analog of a phosphotyroinse-containing peptide can be synthesized according to the method of Y.K. Shue et al. (1987) Tetrahedron Letters 28:3225. Referring to the illustrated example, Boc-amino L-Ile is converted to the corresponding ⁇ -amino aldehyde, which is treated with a vinylcuprate to yield a diastereomeric mixture of alcohols, which are carried on together.
  • the allylic alcohol is acetylated with acetic anhydride in pyridine, and the olefin is cleaved with osmium tetroxide/sodium periodate to yield the aldehyde, which is condensed with the Wittig reagent derived from a protected threonine precursor, to yield the allylic acetate.
  • the allylic acetate is selectively hydrolyzed with sodium carbonate in methanol, and the allylic alcohol is treated with triphenylphosphine and carbon tetrabromide to yield the allylic bromide.
  • This compound is reduced with zinc in acetic acid to give the transposed trans olefin as a mixture of diastereomers at the newly-formed center.
  • the diastereomers are separated and the pseudodipeptide is obtained by selective transfer hydrogenolysis to unveil the free carboxylic acid.
  • the pseudodipeptide is then coupled at the C-terminus with a suitably protected phosphotyrosine residue, and at the N-terminus with the protected threonine residue, by standard techniques, to yield the protected tetrapeptide isostere.
  • the terapeptide is then further condensed with the olefinic tripeptide analog derived by similar means for Ser-Leu- Leu.
  • the protecting groups are then removed with strong acid to yield the desired peptide analog, which can be further purified by HPLC.
  • Other pseudodipeptides can be made by the method set forth above merely by substitution of the appropriate starting Boc amino acid and Wittig reagent. Variations in the procedure may be necessary according to the nature of the reagents used, but any such variations will be purely routine and will be obvious to one of skill in the art.
  • pseudodipeptides synthesized by the above method to other pseudodipeptides, to make peptide analogs with several olefinic functionalities in place of amide functionalities.
  • pseudodipeptides corresponding to pTyr-Ser, Thr-Ile, Ser-Leu, etc. could be made and then coupled together by standard techniques to yield an analog of the ITIM peptide which has alternating olefinic bonds between residues.
  • Still another class of peptidomimetic derivatives include the phosphonate derivatives, such as the partially phosphonate derivatived TITYSSL peptide:
  • a core ITIM motif for PTPIC activation is given by the general formula (I V)XYXX(L V), preferably the tyrosine is phosphorylated. Accordingly, each of the exemplary peptidomimetics above can be derived to correspond to the hexameric ITYSSL core ITIM sequence.
  • the ITIM mimetope will be able to cross a lipid bilayer, such as a plasma membrane of a cell.
  • Mimetopes capable of crossing a lipid bilayer can be organic molecules, in particular carbohydrate-based molecules.
  • a compound of the present invention can include concatomers, wherein one or more ITIM peptides are linked together. As described above, various peptidomimetic derivatives of the peptides can be generated. This invention further contemplates a method of generating sets of combinatorial libraires of the subject ITIM motifs which is especially useful for identifying potential variant sequences (e.g. homologs) that are functional in binding to a regulatory target molecule.
  • ITIM homologs can be engineered by the present method to provide more efficient binding to PTPIC.
  • combinatorially-derived homologs can be generated which have a enhanced potency relative to ITIMs generated from naturally occurring proteins.
  • mutagenesis can give rise to homologs which have intracellular half-lives dramatically different than the corresponding wild-type ITIM.
  • the altered peptide can be rendered either more stable or less stable to proteolytic degradation or other cellular process which result in destruction of, or otherwise inactivation of, the peptide.
  • Such homologs can be utilized to alter the envelope of therapeutic expression by modulating the half-life of the peptide. For instance, a short half-life can give rise to more transient biological effects and can allow tighter control of peptide levels within the cell.
  • the amino acid sequences for a population of ITIM motifs are aligned, preferably to promote the highest homology possible.
  • a population of variants can include, for example, Fc ⁇ RIIB, Ly49, or NKIRp58 (see Figure 1 ) from one or more cell types or species.
  • Amino acids which appear at each position of the aligned sequences are selected to create a degenerate set of combinatorial sequences.
  • the presence or absence of amino acids from an aligned sequence of a particular variant is relative to a chosen consensus length of a reference sequence, which can be real or artificial.
  • deletions in the sequence of a variant relative to the reference sequence can be represented by an amino acid space (-), while insertional mutations in the variant relative to the reference sequence can be disregarded and left out of the sequence of the variant when aligned.
  • ITIM sequences reveals a consensus sequence of (I/V)XYXX(L V) (see Figure 1 ).
  • combinatorial libraries can be generated from this portion of ITIM peptides, the members of which can be expressed in the absence of other portions of receptor proteins, as a part of a receptor protein in which other portions of the protein are static (e.g. an Fc ⁇ R, NKIR, etc.) in which only residues corresponding to the ITIM core sequence are varied by combinatorial mutagenesis, or as part of an unrelated fusion protein, e.g., as part of a phage coat protein or thioredoxin protein.
  • a library of ITIM homologs can be generated based on the receptor ITIM sequences of Figure 1 so as to have an amino acid sequence represented by the degenerate formula:
  • each of Xaa(l)-Xaa(3) are selected from one of the amino acid residues of the same position in Figure 1, e.g., Xaa(l) can be a Val, Ile, Leu, Ser, Thr, Asp or His; Xaa(2) can be an Ala, Val, Ser or Thr; and Xaa(3) can be a Leu, Ile, Thr, Net, Gin, Glu or Asp.
  • Xaa(l ) can be a Gly, Ala, Val, Ile, Leu, Ser, Thr, Cys, Glu, Asp, Lys, Arg or His
  • Xaa(2) can be a Gly, Ala, Val, Ile, Leu, Ser, Cys or Thr
  • Xaa(3) can be a Gly, Ala, Val, Ile, Leu, Ser, Cys, Thr, Met, Asn, Gin, Glu or Asp.
  • amino acid replacement at degenerate positions can be based on steric criteria, e.g. isosteric replacement, without regard for polarity or charge of amino acid sidechains.
  • completely random mutagenesis of one or more of the variant positions (Xaa) can be carried out, e.g., each of Xaa(l)-(3) can be any of the 20 amino acids (or other analogs thereof).
  • the ITIM library can be derived by combinatorial chemistry, such as by techniques which are available in the art for generating combinatorial libraries of small organic/peptide libraries. See, for example, Blondelle et al. (1995) Trends Anal. Chem. 14:83; the Affymax U.S. Patents 5,359,1 15 and 5,362,899; the Ellman U.S. Patent 5,288,514; the Still et al. PCT publication WO 94/08051; Chen et al. (1994) JACS 1 16:2661 ; Kerr et al. (1993) JACS 1 15:252; PCT publications WO92/10092, WO93/09668 and WO91/07087; and the Lerner et al. PCT publication WO93/20242).
  • the combinatorial peptide library is produced by way of a degenerate library of genes encoding a library of polypeptides which each include at least a portion of potential ITIM sequences.
  • a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential ITIM nucleotide sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g. for phage display) containing the set of ITIM peptide sequences therein.
  • the gene library of potential ITIM homologs can be generated from a degenerate oligonucleotide sequence.
  • Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then be ligated into an appropriate gene for expression.
  • the purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential ITIM sequences.
  • the synthesis of degenerate oligonucleotides is well known in the art (see for example, Narang, SA (1983) Tetrahedron 39:3; Itakura et al. (1981) Recombinant DNA, Proc 3rd Cleveland Sympos.
  • a wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of ITIM sequences.
  • the most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected.
  • Such illustrative assays are amenable to high through-put analysis as necessary to screen large numbers of degenerate sequences created by combinatorial mutagenesis techniques.
  • the ITIM gene library can be expressed as a fusion protein on the surface of a viral particle.
  • a viral particle For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at very high concentrations, a large number of phage can be screened at one time. Second, since each infectious phage displays the combinatorial gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection.
  • E.coli filamentous phages Ml 3, fd, and fl are most often used in phage display libraries, as either of the phage gill or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267:16007-16010; Griffths et al. (1993) EMBO J 12:725-734; Clackson et al. (1991) Nature 352:624-628; and Barbas et al.
  • the recombinant phage antibody system (RPAS, Pharmacia Catalog number 27-9400-01) can be easily modified for use in expressing and screening ITIM motif combinatorial libraries of the present invention.
  • the pC ANTAB 5 phagemid of the RPAS kit contains the gene which encodes the phage gill coat protein.
  • the ITIM combinatorial gene library can be cloned into the phagemid adjacent to the gill signal sequence such that it will be expressed as a gill fusion protein. After ligation, the phagemid is used to transform competent E. coli TGI cells.
  • Transformed cells are subsequently infected with M13KO7 helper phage to rescue the phagemid and its candidate ITIM gene insert.
  • the resulting recombinant phage contain phagemid DNA encoding a specific candidate ITIM peptide, and display one or more copies of the corresponding fusion coat protein.
  • the phage-displayed candidate proteins which are capable of, for example, binding a PTPIC target, are selected or enriched by panning.
  • the phage library can be panned on glutathione immobilized PTP1C-GST fusion proteins, and unbound phage washed away from the cells.
  • the bound phage is then isolated, and if the recombinant phage express at least one copy of the wild type gill coat protein, they will retain their ability to infect E coli. Thus, successive rounds of reinfection of E. coli, and panning will greatly enrich for ITIM homologs which can then be screened for further biological activities in order to determine biological effects. Subsequent selection, e.g. of a reduced set of variants from the library, may then be based upon more meaningful criteria rather than simple PTPlC-binding ability. For instance, intracellular half-life or selectivity can become selection criteria in secondary screens.
  • a formulation of the present invention can include a regulatory reagent that is capable of altering the activity of a molecule including PTPIC, PTPID, ITIM- pl60 and ITIM-p70 in a cell in such a manner that the activity of said molecule is altered resulting in regulation of hematopoietic cell function.
  • a formulation of the present invention comprises one or more peptides having the amino acid sequence TA ⁇ NTITYS ⁇ LLKH, GA ⁇ NTITYSLLMH, or mimetopes thereof.
  • the tyrosine residue is phosphorylated.
  • an ITIM is represented by one of: VTYAQL, IVYTEL, VTYTQL, IVYTEL, VTYAQL, ILYTEL, VTYSMV, VTYTTL, VTYSTV, VIYSDL, or ITYAEL, and preferably the tyrosine residue is phosphorylated.
  • an ITIM comprises one of ITYSLL or IXYXXL, and more preferably the tyrosine residue iw phosphorylated.
  • the formulation comprises (I/V)XYXX(L/V), and preferably the tyrosine residue is phosphorylated.
  • the present invention provides pharmaceutically acceptable compositions which comprise a therapeutically-effective amount of one or more of the ITIM mimetics described herein, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
  • the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intravectally, for example, as a pessary, cream or foam; or (5) as an aerosol or micronized powder spray, such as for inhalation.
  • therapeutically-effective amount means that amount of a compound, material, or composition comprising an ITIM peptide or peptidomimetic of the present invention which is effective for producing some desired therapeutic effect by inhibiting or, alternatively, potentiating an intracellular signalling pathway in at least a sub- population of cells in an animal and thereby altering the biological consequences of that pathway in the treated cells, at a reasonable benefit/risk ratio applicable to any medical treatment.
  • an effective amount of a regulatory reagent to contact a cell with includes an amount capable of regulating a signal transduction pathway in a B cell.
  • a preferred effective amount of a regulatory reagent comprises an amount that is capable of reducing B cell receptor activation in a cell contacted with the reagent.
  • a more preferred effective amount of a regulatory reagent comprises an amount that is capable of dephosphorylating (i.e., reducing the extent of phosphorylation) of one or more signal transduction molecules functionally associated with a B cell receptor (i.e., a molecule, the activity of which is stimulated or inhibited by antigen binding to the B cell receptor).
  • An even more preferred effective amount of a regulatory reagent comprises an amount that is capable of inducing dephosphorylation of, CD 19, Fyn, Lyn, Syk, PI-3 kinase, Ig ⁇ , Ig ⁇ , Fc ⁇ RI ⁇ , Fc ⁇ RI ⁇ , Fc ⁇ RIIA, CD3 ⁇ , CD3 ⁇ , TCR-zeta, She and/or PLC ⁇ .
  • the amount of dephosphorylation of a signal transduction molecule can be measured using methods known to those of skill in the art. In particular, dephosphorylation assays can be performed using the methods described in detail in Example 5.
  • an effective amount of a regulatory reagent to contact a cell with includes an amount capable of reducing the extent of intracellular calcium mobilization resulting from B cell receptor cross-linking, such reduction compared with the extent of intracellular calcium mobilization resulting from B cell receptor cross-linking in the absence of the reagent.
  • an effective amount of a regulatory reagent comprises an amount capable of reducing calcium mobilization by about 2-fold, more preferably by about 3 -fold and even more preferably by about 4-fold, when compared with the extent of intracellular calcium mobilization resulting from BCR cross-linking in the absence of the reagent.
  • the amount of calcium mobilization in response to BCR cross ⁇ linking can be measured using methods known to those of skill in the art. In particular, the calcium mobilization can be measured using the general methods described in Example 6.
  • an effective amount of a regulatory reagent to contact a cell with includes an amount capable of reducing the amount of histamine produced by a cell.
  • an effective amount of a regulatory reagent comprises an amount capable of reducing the level of histamine production by a cell by about 2-fold.
  • an effective amount of a regulatory reagent for use with the method of the present invention comprises an amount that alters the level of IL-5 production by a cell preferably by about 2-fold, more preferably by about 3-fold and even more preferably by about 4-fold.
  • an effective amount of a regulatory reagent for use with the method of the present invention comprises an amount that alters the level of IL-8 production by a cell preferably by about 2- fold, more preferably by about 3-fold and even more preferably by about 4-fold.
  • the concentration of histamine, IL-5 and IL-8 produced by a cell can be measured using methods known to those of skill in the art.
  • the concentration of IL-5 or IL-8 can be measured by, for example, using antibodies that specifically bind to 11-5 or IL-8, respectively, in an enzyme-linked immunoassay or a radioimmunoassay.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically-acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject peptide and peptidomimetic agents from one organ, or portion of the body, to another organ, or portion of the body.
  • a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject peptide and peptidomimetic agents from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (1 1) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydrox
  • certain embodiments of the subject ITIM mimetics may contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable acids.
  • pharmaceutically-acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts of peptides or peptidomimetics of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified peptide or peptidomimetic in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci 66:1-19).
  • the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable bases.
  • pharmaceutically-acceptable salts in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of peptides and peptidomimetics of the present invention.
  • salts can likewise be prepared in situ during the final isolation and purification of the peptides or peptidomimetics, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine.
  • a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine.
  • Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
  • Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.
  • wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
  • Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol, and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the peptide or peptidomimetic which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
  • Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a peptide or peptidomimetic of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • lozenges using a flavored basis, usually sucrose and acacia or tragacanth
  • a peptide or peptidomimetic of the present invention may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as par
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface- active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered peptide or peptidomimetic moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
  • compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • Suspensions in addition to the active peptides or peptidomimetics, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and. therefore, will melt in the rectum or vaginal cavity and release the active peptidomimetic.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and. therefore, will melt in the rectum or vaginal cavity and release the active peptidomimetic.
  • Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of a peptide or peptidomimetic of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • the ointments, pastes, creams and gels may contain, in addition to an active peptide or peptidomimetic of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
  • dosage forms can be made by dissolving or dispersing the peptidomimetic in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the peptidomimetic across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the peptidomimetic in a polymer matrix or gel.
  • Opthalmic formulations are also contemplated as being within the scope of this invention.
  • compositions of this invention suitable for parenteral administration comprise one or more peptides or peptidomimetics of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged abso ⁇ tion of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay abso ⁇ tion such as aluminum monostearate and gelatin.
  • adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as
  • the abso ⁇ tion of the drug in order to prolong the effect of a drug, it is desirable to slow the abso ⁇ tion of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amo ⁇ hous material having poor water solubility. The rate of abso ⁇ tion of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed abso ⁇ tion of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • Injectable depot forms are made by forming microencapsule matrices of the subject peptides or peptidomimetics in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
  • the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
  • the preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhilation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • peptides and peptidomimetics may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
  • the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular peptide or peptidomimetic of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular peptidomimetic employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a peptide or peptidomimetic of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day.
  • the effective daily dose of the active peptide or peptidomimetic may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the peptide or peptidomimetic as a pharmaceutical formulation (composition).
  • nucleic acid molecule that encodes a peptidyl form of the compounds of the present invention as herein disclosed.
  • references to nucleic acids also refer to nucleic acid molecules.
  • an isolated nucleic acid molecule is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation). As such, "isolated” does not necessarily reflect the extent to which the nucleic acid molecule has be purified.
  • An isolated nucleic acid molecule can include DNA, RNA, or hybrid or derivatives of either DNA or RNA.
  • Nucleic acid molecules of the present invention can include a regulatory region that controls expression of the nucleic acid molecule (e.g., transcription or translation control regions), full-length or partial coding regions, and combinations thereof. Any portion of a nucleic acid molecule the present invention can be produced by (1) isolating the molecule from its natural milieu; (2) using recombinant DNA technology (e.g., PCR Amplification, cloning); or (3) using chemical synthesis methods.
  • a nucleic acid molecule of the present invention can include functional equivalents of natural nucleic acid molecules encoding a compound of the present invention including, but not limited to, natural allelic variants and modified nucleic acid molecules in which nudeotides have been inserted, deleted, substituted, and/or inverted in such a manner that such modifications do not substantially interfere with the nucleic acid molecules' ability to encode a compound of the present invention capable of regulating signal transduction.
  • Preferred functional equivalents include nucleic acid sequences that are capable of hybridizing under stringent conditions, to: at least a portion of a nucleic acid molecule encoding an ITIM peptide derived from, e.g., an Fc ⁇ R, CD22, NKIRp58 or Ly49 protein. Stringent hybridization conditions are described in Sambrook et al, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Labs Press, 1989, which is inco ⁇ orated herein by reference in its entirety).
  • nucleic acid molecules As guidance in determining what particular modifications can be made to any particular nucleic acid molecule, one of skill in the art should consider several factors that, without the need for undue experimentation, permit a skilled artisan to appreciate workable embodiments of the present invention. For example, such factors include modifications to nucleic acid molecules performed in a manner so as to maintain particular functional regions of the encoded compound of the present invention including: an ITIM motif capable of being bound by PTPIC, PTPID, ITIM-pl60 and/or ITIM-p70, capable of regulating the activity of such proteins and a functional phosphatase domain.
  • an ITIM motif capable of being bound by PTPIC, PTPID, ITIM-pl60 and/or ITIM-p70, capable of regulating the activity of such proteins and a functional phosphatase domain.
  • Functional tests of these various characteristics allows one of skill in the art to determine what modifications to the nucleic acid molecules would be appropriate and which would not.
  • Functional tests of these various characteristics allows one of skill in the art to determine what modifications to the nucleic acid molecules would be appropriate and which would not.
  • an ITIM nucleic acid of the present invention encodes a polypeptide including an ITIM peptide sequence represented in the consensus polypeptide (I/V)XYXX(L/V).
  • a preferred ITIM nucleic acid includes a coding sequence for an ITIM motif comprising an amino acid sequence ITYSLL or IXYXXL such as may be found in the peptides TAENTITYSELLKH, GAENTITYSLLMH.
  • ITIM nucleic acid molecules encode ITIM peptides including such ITIM peptide sequences as VTYAQL, IVYTEL,VTYTQL, IVYTEL, VTYAQL, ILYTEL, VTYSMV, VTYTTL, VTYSTV, VIYSDL, or ITYAEL.
  • an isolated nucleic acid molecule of the present invention includes a nucleic acid sequence that encodes PTPIC, PTPID, ITIM-pl60 and/or ITIM-p70, as disclosed herein.
  • a PTPIC nucleic acid molecule can include a nucleic acid sequence encoding at least a portion of a PTPIC protein having an amino acid sequence as disclosed in (Shen et al., Nature 352:736-739, 1991 ; Matthews et al., Mol. Cell. Biol. 12:2396-2405, 1992; and Plutzky et al., Proc. Natl. Acad. Sci. USA 89:1 123-1127, 1992), or a mimetope thereof.
  • the nucleic acid encodes an ITIM-binding SH2 domain from PTPIC.
  • At least a portion of a nucleic acid molecule encoding an ITIM peptide can be covalently associated (using standard recombinant DNA methods) to any other sequence that codes for at least a portion of a distinct component (e.g., control element) to produce an ITIM peptide of the present invention.
  • the sequences can be attached in such a manner so that the sequences are transcribed in-frame, thereby producing a functional ITIM peptide capable of regulating the activity of an SH2 containing tyrosine phosphatase.
  • nucleic acid encoding the subject peptides can be used to generate a chimeric gene encoding a fusion protein.
  • a nucleic acid sequence can be added that encodes a signal sequence, e.g., a sequence which directs secretion of the recombinantly produced ITIM peptide from the host cell.
  • Nucleic acid sequences encoding a signal sequence are covalently associated (by base pair linkage) to the 5' end (amino terminal end) of a nucleic acid molecule.
  • Useful signal sequences are known in the art (c.f, Achstetter et al. (1992) Gene 110:25).
  • Preferred signal or leader segments are segments naturally associated with a Fc ⁇ R, CD22, NKIRp58, or Ly49.
  • Preferred transmembrane segments include segments that are naturally associated with a Fc ⁇ R, CD22, NKIRp58, or Ly49.
  • chimeric nucleic acids sequences can be used which provide the peptide with at least one transmembrane segment (including stop transfer sequences) capable of anchoring the peptide to a lipid-containing target molecule or membrane.
  • a nucleic acid sequence encoding a transmembrane segment is covalently associated (by base pair linkage) to one of either the 5' or 3' end of a nucleic acid molecule encoding an ITIM peptide of the present invention.
  • a chimeric nucleic acid molecule encoding a fusion polypeptide comprising the peptide of the present invention with a transmembrane domain at its N-terminus can be used to provide a membrane anchored form of the ITIM peptides in which the peptide of interest is presented at the cytoplasmic face of the cell membrane.
  • a chimeric gene can be constructed which provides a nucleic acid sequence encoding a transmembrane sequence ligated to the 3' end of a nucleic acid sequence encoding an ITIM so as to provide that peptide at the extracellular face of the cell membrane.
  • signal peptides and/or transmembrane sequences and their orientation relative to the ITIM peptide sequences in the chimeric gene can be used to localize the subject peptides in various intracellular compartments.
  • membrane anchoring motifs can be employed, such as to direct prenylation of a chimeric peptide (e.g., using a farnesyltransferase or geranylgeranyl transferase recognition sequence), or to direct attachment of phosphatidylinositol to the peptide.
  • fusion proteins can enhance production/purification of peptides.
  • inclusion of a fusion segment as part of a compound of the present invention can enhance the stability of the compound during production, storage and/or use.
  • a fusion segment can function as a tool to simplify purification of a compound of the present invention, such as to enable purification of the resultant fusion protein using affinity chromatography.
  • an ITIM peptide can be generated as a glutathione-S- transferase (GST) fusion protein.
  • Such GST-fusion proteins can enable easy purification of the subject peptides, as for example by the use of glutathione-derivatized matrices (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. (N.Y.: John Wiley & Sons, 1991)).
  • Addition of a proteolytic cleavage site, such as a Factor X cleavage site, between the GST moiety and subject peptide permits release of the subject peptide.
  • a fusion gene coding for a purification leader sequence such as a poly- (His)/enterokinase cleavage site sequence
  • a purification leader sequence such as a poly- (His)/enterokinase cleavage site sequence
  • the purification leader sequence can then be subsequently removed by treatment with enterokinase (e.g., see Hochuli et al. (1987) J. Chromatography 411 :177; and Janknecht et al. PNAS 88:8972).
  • fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
  • the chimeric gene can be synthesized by conventional techniques including automated DNA synthesizers.
  • PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology. Eds. Ausubel et al. John Wiley & Sons: 1992).
  • the linker can be of natural origin, such as a sequence determined to exist in random coil between two domains of a protein.
  • the linker can be of synthetic origin.
  • the sequence (Gly4Ser)3 can be used as a synthetic unstructured linker. Linkers of this type are described in Huston et al. (1988) PNAS 85:4879; and U.S. Patent No. 5,091,513.
  • the present invention also includes a recombinant molecule comprising a nucleic acid molecule encoding a compound of the present invention operatively linked to a vector capable of being expressed in a host cell.
  • operatively linked refers to insertion of a nucleic acid sequence into an expression vector in such a manner that the sequence is capable of being expressed when transformed into a cell.
  • an "expression vector” is an RNA or DNA vector capable of transforming a host cell and effecting expression of an appropriate nucleic acid molecule, preferably replicating within the host cell.
  • An expression vector can be either prokaryotic or eukaryotic, and typically is a virus or a plasmid.
  • prokaryotic systems are bacterial strains, including, but not limited to various strains of E. coli various strains of bacilli or various species of Pseudomonas.
  • prokaryotic systems plasmids are used that contain replication sites and control sequences derived from a species compatible with a host cell. Control sequences can include, but are not limited to promoters, operators, enhancers, ribosome binding sites, and Shine-Dalgarno sequences.
  • Expression systems useful in eukaryotic host cells comprise promoters derived from appropriate eukaryotic genes.
  • Useful mammalian promoters include early and late promoters from SV40 or other viral promoters such as those derived from baculovirus, polyoma virus, adenovirus, bovine papilloma virus or avian sarcoma virus.
  • Expression vectors of the present invention include any vectors that function (i.e., direct gene expression) in recombinant cells of the present invention including bacterial, yeast, other fungal, insect, plant mammalian cells.
  • An expression system can be constructed from any of the foregoing control elements operatively linked to the nucleic acid molecules of the present invention using methods known to those skilled in the art (see, for example, Sambrook, et al. ibid.).
  • Host cells of the present invention can be: cells naturally capable of producing a compound of the present invention; or cells that are capable of producing a compound of the present invention when transfected with a nucleic acid molecule encoding a compound of the present invention.
  • Host cells of the present invention include, but are not limited to, bacterial, fungal, insect, plant and mammalian cells. More preferred host cells include Escherichia, Bacillus, Saccharomyces, SF9 and Drosophila.
  • a recombinant cell is preferably produced by transforming a host cell with one or more recombinant molecules, each comprising one or more nucleic acid molecules of the present invention operatively linked to an expression vector containing one or more transcription control sequences.
  • a recombinant molecule of the present invention is a molecule that can include at least one of the nucleic acid molecules heretofore described, operatively linked to at least one of any transcription control sequence capable of effectively regulating expression of the nucleic acid molecule(s) in the cell to be transformed.
  • recombinant DNA technologies can improve expression of transformed nucleic acid molecules by manipulating, for example, the number of copies of the nucleic acid molecules within a host cell, the efficiency with which those nucleic acid molecules are transcribed, and the efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications.
  • Recombinant techniques useful for increasing the expression of nucleic acid molecules of the present invention include, but are not limited to, operatively linking nucleic acid molecules to high-copy number plasmids, integration of the nucleic acid molecules into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals, modification of nucleic acid molecules of the present invention to correspond to the code on usage of the host cell, deletion of sequences that destabilize transcripts, and use of control signals that temporarily separate recombinant cell growth from recombinant enzyme production during fermentation.
  • the activity of an expressed recombinant peptide of the present invention may be improved by fragmenting, modifying, or derivitizing nucleic acid molecules encoding such a peptide.
  • recombinant cells of the present invention can be used to produce a compound of the present invention by culturing such cells under conditions effective to produce such a compound, and recovering the compound.
  • Effective conditions to produce a compound of the present invention include, but are not limited to. appropriate media, bioreactor, temperature, pH and oxygen conditions that permit peptide production.
  • An appropriate medium refers to any medium in which a cell of the present invention, when cultured, is capable of producing a compound of the present invention.
  • An effective medium is typically an aqueous medium comprising assimilable carbohydrate, nitrogen and phosphate sources, as well as appropriate salts, minerals, metals, and other nutrients, such as vitamins.
  • the medium may comprise complex nutrients or may be a defined minimal medium.
  • the medium may also contain chemical reagents which select for expression of particular recombinant molecules.
  • Such reagents include, but are not limited to, neomycin, ampicillin, tetracycline, chloramphenicol and mycophenolic acid.
  • resultant compounds of the present invention may either remain within the recombinant cell; be secreted into the fermentation medium; be secreted into a space between two cellular membranes, such as the piroplasmic space in E.coli; or be retained on the outer surface of a cell or viral membrane.
  • the phrase "recovering the compound” refers simply to collecting the whole fermentation medium containing the compound and need not imply additional steps of separation or purification.
  • a compound of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatafocusing, differential solubilization, and immunoprecipitation.
  • a compound of the present invention is preferably retrieved in "substantially pure” form. As used herein, “substantially pure” refers to a purity that allows for the effective use of the compound as a therapeutic composition or in an assay system.
  • a substantially pure compound of the present invention should be capable of regulating the activity of an SH2 domain containing tyrosine phosphatase in a cell without exhibiting substantial toxicity to such cell.
  • the expression vector of the present application can also be used to generate a variety of gene therapy compositions. Accordingly, the expression constructs of the subject ITIM peptides may be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively transfecting cells in vivo with a recombinant gene.
  • Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno- associated virus, and he ⁇ es simplex virus- 1, or recombinant bacterial or eukaryotic plasmids.
  • Viral vectors can be used to transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramacidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO4 precipitation carried out in vivo.
  • lipofectin cationic liposomes
  • derivatized e.g. antibody conjugated
  • polylysine conjugates e.g. antibody conjugated
  • gramacidin S e.g. antibody conjugated
  • artificial viral envelopes or other such intracellular carriers e.g. direct injection of the gene
  • a preferred approach for in vivo introduction of nucleic acid encoding one of the subject proteins into a cell is by use of a viral vector containing nucleic acid, e.g. a cDNA, encoding the gene product.
  • a viral vector containing nucleic acid e.g. a cDNA
  • Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid.
  • molecules encoded within the viral vector e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.
  • Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of exogenous genes in vivo, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host.
  • a major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population.
  • the development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D.
  • recombinant retrovirus can be constructed in which part of the retroviral coding sequence (gag, pol, env) has been replaced by nucleic acid encoding one of the subject peptides, rendering the retrovirus replication defective.
  • the replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al., (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals.
  • retroviruses examples include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art.
  • suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include ⁇ Crip, ⁇ Cre, ⁇ 2 and ⁇ Am.
  • Retroviruses have been used to introduce a variety of genes into many different cell types, including neural cells, epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and or in vivo (see for example Eglitis et al., (1985) Science 230:1395-1398; Danos and Mulligan, (1988) Proc. Natl. Acad. Sci.
  • retroviral-based vectors it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO93/25234, WO94/06920, and WO94/1 1524).
  • strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies specific for cell surface antigens to the viral env protein (Roux et al., (1989) Proc. Natl. Acad. Sci. USA 86:9079- 9083; Julan et al., (1992) J.
  • Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the env protein to an asialoglycoprotein), as well as by generating fusion proteins (e.g. single-chain antibody/ewv fusion proteins).
  • This technique while useful to limit or otherwise direct the infection to certain tissue types, and can also be used to convert an ecotropic vector in to an amphotropic vector.
  • retroviral gene delivery can be further enhanced by the use of tissue- or cell-specific transcriptional regulatory sequences which control expression of the recombinant gene of the retroviral vector.
  • Another viral gene delivery system useful in the present invention utilizes adenovirus- derived vectors.
  • the genome of an adenovirus can be manipulated such that it encodes a gene product of interest, but is inactivate in terms of its ability to replicate in a normal lytic viral life cycle (see, for example, Berkner et al., (1988) BioTechniques 6:616; Rosenfeld et al., (1991) Science 252:431-434; and Rosenfeld et al., (1992) Cell 68:143-155).
  • adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus are well known to those skilled in the art.
  • Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld et al., (1992) cited supra), endothelial cells (Lemarchand et al., (1992) Proc. Natl. Acad. Sci.
  • virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity.
  • introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA).
  • the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al., supra; Haj-Ahmand and Graham (1986) J Virol. 57:267).
  • adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts of the viral El and E3 genes but retain as much as 80% of the adenoviral genetic material (see, e.g., Jones et al., (1979) Cell 16:683; Berkner et al., supra; and Graham et al., in Methods in Molecular Biology, E.J. Murray, Ed. (Humana, Clifton, NJ, 1991) vol. 7. pp. 109-127).
  • Expression of the inserted ITIM gene can be under control of, for example, the El A promoter, the major late promoter (MLP) and associated leader sequences, the E3 promoter, or exogenously added promoter sequences.
  • MLP major late promoter
  • Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a he ⁇ es virus, as a helper virus for efficient replication and a productive life cycle.
  • AAV adeno-associated virus
  • Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb.
  • An AAV vector such as that described in Tratschin et al., (1985) Mol. Cell. Biol. 5:3251-3260 can be used to introduce DNA into cells.
  • a variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al., (1984) Proc. Natl. Acad. Sci.
  • he ⁇ es virus vectors may provide a unique strategy for persistence of the recombinant gene in cells of the central nervous system and ocular tissue (Pepose et al., (1994) Invest Ophthalmol Vis Sci 35:2662-2666)
  • non-viral methods can also be employed to cause expression of a recombinant ITIM peptide in the tissue of an animal.
  • Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules.
  • non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the peptide-encoding gene by the targeted cell.
  • Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes.
  • a gene encoding a ITIM peptide can be entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens of the target tissue (Mizuno et al., (1992) No Shinkei Geka 20:547-551; PCT publication WO91/06309; Japanese patent application 1047381; and European patent publication EP-A-43075).
  • lipofection of lymphoma cells can be carried out using liposomes tagged with monoclonal antibodies against lymphomaa-associated antigens. Liposome delivery is also a well known method for delivering small peptides and even proteins directly into cells and can be used to directly deliver ITIM peptides and mimetics.
  • the gene delivery system comprises an antibody or cell surface ligand which is cross-linked with a gene binding agent such as poly- lysine (see, for example, PCT publications WO93/04701, WO92/22635, WO92/20316, WO92/19749, and WO92/06180).
  • a gene binding agent such as poly- lysine
  • the subject peptide gene constructs can be used to transfect hepatocytic cells in vivo using a soluble polynucleotide carrier comprising an asialoglycoprotein conjugated to a polycation, e.g. poly-lysine (see U.S. Patent 5,166,320).
  • the gene delivery systems can be introduced into a patient by any of a number of methods, each of which is familiar in the art.
  • a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the construct in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the gene, or a combination thereof.
  • initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized.
  • the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen et al., (1994) Proc. Natl. Acad. Sci. USA 91 : 3054-3057).
  • Another aspect of the present invention relates to a variety of drug screening assays designed to identify compounds which can modulate ITIM-dependent signal transduction pathways.
  • high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time.
  • Assays which are performed in cell-free systems such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound.
  • test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of the drug on the molecular target as may be manifest, for example, in an alteration of binding affinity between various signal transduction proteins.
  • ITIM/TPT1C interaction is described below for illustrative pu ⁇ osed, it will be clear that other interactions described herein, such as ITIM/PTP1D, ITIM/pl60, ITIM p70, and PTP1C/CD19, are each potential therapeutic targets and accordingly may be cast in drug screening assays similar to those described below.
  • the compound of interest is contacted with an isolated and purified polypeptide which is ordinarily capable of binding to an ITIM polypeptide sequence.
  • an isolated and purified polypeptide which is ordinarily capable of binding to an ITIM polypeptide sequence.
  • PTPIC polypeptide to a mixture of the compound and PTPIC polypeptide is then added a composition containing an ITIM polypeptide.
  • the ITIM may be in the form of a short peptide, or may be a larger soluble portion of a protein containing an ITIM sequence, such as the cytoplasmid comain of Fc ⁇ RIIBl .
  • Detection and quantification of ITIM/PTP1C complexes provides a means for determining the compound's efficacy at inhibiting (or potentiating) complex formation between the ITIM and PTPIC polypeptides.
  • the efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations of the test compound.
  • a control assay can also be performed to provide a baseline for comparison.
  • isolated and purified ITIM is added to a composition containing the PTPIC protein, and the formation of ITIM/PTP1C complex is quantitated in the absence of the test compound. It will be understood that, in general, the order in which the reactants may be admixed can be varied, and can be admixed simultaneously.
  • Complex formation between the target PTPIC polypeptide and ITIM polypeptide may be detected by a variety of techniques. For instance, modulation of the formation of complexes can be quantitated using, for example, detectably labelled proteins such as radiolabelled (e.g. 32 P, 35 S, 14 C or 3 H), fluorescently labelled (e.g. FITC), or enzymatically labelled PTPIC or ITIM polypeptides, by immunoassay, or by chromatographic detection.
  • detectably labelled proteins such as radiolabelled (e.g. 32 P, 35 S, 14 C or 3 H), fluorescently labelled (e.g. FITC), or enzymatically labelled PTPIC or ITIM polypeptides, by immunoassay, or by chromatographic detection.
  • detectably labelled proteins such as radiolabelled (e.g. 32 P, 35 S, 14 C or 3 H), fluorescently labelled (e.g. FITC), or enzymatically labelled PTPIC or ITIM polypeptides, by
  • binding of ITIM to PTPIC in the presence and absence of a candidate agent, can be accomplished in any vessel suitable for containing the reactants. Examples include microtitre plates, test tubes, and micro-centrifuge tubes.
  • a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix.
  • glutathione-S-transferase/PTPlC (GST/PTP1C) fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the ITIM polypeptide, e.g. an 35 S-labeled ITIM polypeptide, and the test compound, and the mixture incubated under conditions conducive to complex formation, e.g. at physiological conditions for salt and pH, though slightly more stringent conditions may be desired, e.g., at 4°C in a buffer containing 0.6M NaCl or a detergent such as 0.1% Triton X-100.
  • glutathione sepharose beads Sigma Chemical, St. Louis, MO
  • glutathione derivatized microtitre plates which are then combined with the ITIM polypeptide, e.g. an 35 S-labeled ITIM polypeptide, and the test compound, and the mixture incubated under
  • the beads are washed to remove any unbound ITIM polypeptide, and the matrix immobilized radiolabel determined directly (e.g. beads placed in scintilant), or in the supernatant after the PTP1C/ITIM complexes are subsequently dissociated.
  • the complexes can dissociated from the matrix, separated by SDS-PAGE, and the level of ITIM polypeptide found in the bead fraction quantitated from the gel using standard electrophoretic techniques such as described in the appended examples.
  • either of the PTPIC or ITIM proteins can be immobilized utilizing conjugation of biotin and streptavidin.
  • biotinylated PTPIC molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit. Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
  • antibodies reactive with the PTPIC but which do not interfere with ITIM binding can be derivatized to the wells of the plate, and the PTPIC trapped in the wells by antibody conjugation.
  • preparations of an ITIM polypeptide and a test compound are incubated in the PTP1C- presenting wells of the plate, and the amount of PTP1C/ITIM complex trapped in the well can be quantitated.
  • Exemplary methods for detecting such complexes include immunodetection of complexes using antibodies reactive with the ITIM polypeptide, or which are reactive with the PTPIC protein and compete for binding with the ITIM polypeptide; as well as enzyme- linked assays which rely on detecting an extrinsic enzymatic activity associated with the ITIM polypeptide.
  • the enzyme can be chemically conjugated or provided as a fusion protein with an ITIM polypeptide.
  • the ITIM polypeptide can be chemically cross-linked or genetically fused with horseradish peroxidase, and the amount of ITIM polypeptide trapped in the complex can be assessed with a chromogenic substrate of the enzyme, e.g. 3,3'-diamino-benzadine terahydrochloride or 4-chloro-l-napthol.
  • a fusion protein comprising the ITIM polypeptide and glutathione-S-transferase can be provided, and complex formation quantitated by detecting the GST activity using 1- chloro-2,4-dinitrobenzene (Habig et al (1974) J Biol Chem 249:7130).
  • antibodies against the protein can be used.
  • the protein to be detected in the complex can be "epitope tagged" in the form of a fusion protein which includes, in addition to the ITIM polypeptide or PTPIC sequence, a second polypeptide for which antibodies are readily available (e.g. from commercial sources).
  • the GST fusion proteins described above can also be used for quantification of binding using antibodies against the GST moiety.
  • Other useful epitope tags include myc-epitopes (e.g., see Ellison et al.
  • the polypeptides of the present invention can be disposed as part of a thioredoxin chimeric protein and the ability of the exogenous peptide to direct binding of the thioredoxin to a target protein can be assessed in the presence and absence of a candidate agent.
  • a modified version of the E. coli thioredoxin (trxA) protein can be used as a larger carrier protein (LaVallie et al., Biotechnology 1 1 :187-193, 1993).
  • the crystal structure of trxA ( ⁇ 12kD) shows that the protein is extremely compact but the active site region which includes glycine 33 and proline 34 forms a protruding loop.
  • the peptide inserted in the protuding loop between Gly33-Pro34 will be displayed on the surface of trxA.
  • proteins expressing peptides inserted in this loop have been successivefully used for the production of antipeptide monoclonal antibodies.
  • Such peptide loops can be digested by enteropeptidase when the inserted peptide carries a recognition site for the enzyme (DDDK).
  • DDDK recognition site for the enzyme
  • the trxA carrier protein has other additional desirable features. First, overexpression of trxA inS. cerevisiae cells does not negatively affect their growth. Second, fusion of insoluble peptides to the trxA protein helps to keep these proteins soluble in E. coli.
  • the trxA fusion proteins localize to the inner periphery of the cytoplasmic membrane in E. coli and can easily be released by osmotic shock.
  • the existence of a unique RsrII restriction site in the DNA encoding glycine 33 and proline 34 allows for easy insertion of peptides
  • an ITIM polypeptide can be provided in the active site loop of thioredoxin, and the ability of that molecule to bind to, for example, PTPIC or PTPID assessed.
  • constructs can be used to generate combinatorial libraries of related ITIMs, and these libraries screened to identify those variants which retain the ability to bind to the target molecule.
  • the above thioredoxin chimeras, and similar constructs thereto, can be used in direct cell-free binding assays. Alternatively, they can be used to generate an interaction trap assay(ITS), utilizing such systems as described in U.S. Patent No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J Biol Chem 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; and Iwabuchi et al. (1993) Oncogene 8:1693-1696. As in the cell-free binding assays, the ITS can be employed for detecting agents which disrupt binding of the ITIM peptide to a target protein, e.g. PTPIC.
  • the interaction trap assay relies on reconstituting in vivo a functional transcriptional activator protein from two separate fusion proteins, one of which comprises the DNA-binding domain of a transcriptional activator fused to a thioredoxin chimera, such as a Thrioredoxin/ITIM chimera.
  • the second fusion protein comprises a transcriptional activation domain (e.g. able to initiate RNA polymerase transcription) fused to, for example, a PTPIC polypeptide, preferably a catalytically inactive mutant.
  • Saccharomyces cerevisiae YPB2 cells are transformed simultaneously with a plasmid encoding a GAL4db-Thioredoxin/ITIM fusion and with a plasmid encoding the GAL4ad domain fused to a regulatory domain of PTPIC.
  • the strain is transformed such that the GAL4-responsive promoter drives expression of a phenotypic marker.
  • the ability to grow in the absence of histidine can depends on the expression of the HIS3 gene.
  • the phenotypic marker (e.g. instead of the HIS3 gene) can be one which provides a negative selection (e.g., are cytotoxic) when expressed such that agents which disrupt ITIM/PTP1C interactions confer positive growth selection to the cells.
  • kits can include: (1) a tyrosine phosphatase; (2) a compound of the present invention capable of stimulating the activity of the tyrosine phosphatase; and (3) a means for measuring the activity of the tyrosine phosphatase. It is within the skill of one in the art to modify a kit of the present invention to identify inhibitory compounds by, for example, adding to the kit a primary target molecule capable of being modified by the tyrosine phosphatase and a means for detecting such modification.
  • the activity of a tyrosine phosphatase can be measured by, for example, measuring dephosphorylation or modification of a primary target molecule, or a phosphorylated fragment thereof, by the phosphatase.
  • Synthetic substrates are also known as for example, p- nitrophenyl phosphate, 3-0-methyl-l-fluoroscein monophosphate or fluorosein diphosphate.
  • Another aspect of the present invention includes a method to identify compounds capable of regulating hematopoietic cell function, the method comprising: (1) contacting a putative regulatory reagent with PTPIC under conditions suitable for maintaining the enzymatic activity of the PTPIC; and (2) identifying whether the compound is capable of regulating hematopoietic cell function by determining the activity of the PTPIC after the step of contacting.
  • the method is performed in vitro by: (1) contacting a putative regulatory compound with PTPIC in a container containing suitable buffer and phosphorylated Fyn peptide; and (2) measuring release of [ 3 P] from the Fyn peptide.
  • the method is performed in a cell-based assay by: (a) contacting a B cell having PTPIC, membrane-bound immunoglobulin and membrane-bound Fc receptor with a putative regulatory compound; (b) contacting the cell with an antibody capable of co-ligating the membrane-immunoglobulin with the membrane-bound Fc receptor; (c) lysing the cell; and (d) determining the state of phosphorylation of an intracellular molecule.
  • Suitable intracellular molecules to measure the phosphorylation of include, but are not limited to, CD 19, Syk, Lyn, Fyn, PI-3 kinase, Ig ⁇ , Ig ⁇ , Fc ⁇ RI ⁇ , Fc ⁇ RI ⁇ , Fc ⁇ RIIA, She and/or PLC ⁇ .
  • the method is performed by: (a) contacting a basophil having PTPIC and membrane-bound Fc receptor with a putative regulatory compound; (b) coligating activating and inhibitory receptors on the cell surface, such as the BCR and Fc ⁇ R or CD16 and NKIRp59 or Ly49; (c) lysing the cell; and (d) determining the state of phosphorylation of an intracellular molecule.
  • Suitable intracellular molecules to measure the phosphorylation of include, but are not limited to, PI-3 kinase, Fc ⁇ RI ⁇ , Fc ⁇ RIII and or PLC ⁇
  • methods to detect the state of phosphorylation of an intracellular molecule include ELISA assays or FACS analysis.
  • a lysed cell can be contacted with an antibody specific for an intracellular molecule bound to an ELISA plate.
  • the plates can be washed and then contacted with an anti-phosphotyrosine antibody bound by a detectable label (e.g., fluorescein, radioisotope or alkaline phosphatase).
  • a detectable label e.g., fluorescein, radioisotope or alkaline phosphatase.
  • the amount of anti-phosphotyrosine antibody bound to the ELISA plate can be measured to determine the extent of phosphorylation or dephosphorylation of an intracellular molecule by a putative regulatory compound.
  • Another aspect of the present invention includes a method to identify a treatment for abnormal hematopoietic cell function, comprising: (1) isolating basophils from a patient; (2) contacting the basophils with ligands including Fab' IgG antibody and whole IgG antibody; and (3) diagnosing abnormal hematopoietic cell function by determining PTPIC activity in the basophils after the step of contacting with the ligand.
  • the basophils used with the present method are isolated from human patients.
  • a cell- based assay of the present invention useful for the identification of compounds capable of modulating (either activating or inhibiting) signal transduction includes the steps of: (a) contacting a cell with a test compound in such a manner that the compound is capable of entering the cell; (b) incubating the compound and the cell so as to allow association of the compound with appropriate intracellular molecules and optionally aggregating cell surface molecules (c) lysing the cell; and (d) determining the state of phosphorylation of an intracellular molecule bound to the compound.
  • Suitable cells include, but are not limited to, mammalian cells.
  • Suitable intracellular molecules include, but are not limited to, src-family tyrosine kinase, in particular Cdl9, Lyn, Fyn, Lck, Blk, Syk, Yes, Btk, Hck, Src, and Zap70.
  • Methods to detect the state of phosphorylation of an intracellular molecule include ELISA assays or FACS analysis.
  • a lysed cell can be contacted with an antibody specific for an intracellular molecule bound to an ELISA plate. The plates can be washed and then contacted with an anti-phosphotyrosine antibody bound by a tag as described in detail above.
  • the amount of anti-phosphotyrosine antibody bound to the ELISA plate can be measured to determine the extent of phosphorylation and, therefore stimulation, of an intracellular molecule by the putative stimulatory compound.
  • Another method for determining the state of phosphorylation of the intracellular molecule includes contacting an antibody specific for an intracellular molecule with the lysed cells in solution.
  • An anti-phosphotyrosine antibody can be added to the solution and analyzed by FACS analysis.
  • the anti-phosphotyrosine antibody can have a fluorescent tag or a second antibody having a tag can be added to the solution.
  • a cell-based assay of the present invention can include the steps of: (a) contacting a cell with a putative inhibitory compound; (b) incubating the compound with the cell so as to allow the compound to bind intracellular molecules; (c) ligating membrane-bound receptors on the surface of the cell; and (d) determining the ability of a putative inhibitory molecule to inhibit calcium mobilization in the cell.
  • Suitable cells include, but are not limited to, mammalian cells.
  • Suitable putative regulatory molecules of include mimetopes of Syk-selective, She-selective or PI-3K-selective peptides of the present invention. Calcium mobilization can be measured using the methods generally described in Justement et al., J. Immunol. 143:881-886, 1989.
  • a cell-based assay of the present invention can include the steps of: (a) contacting a cell with a putative inhibitory compound; (b) incubating the compound with the cell so as to allow the compound to bind intracellular molecules; (c) ligating membrane-bound receptors on the surface of the cell; and (d) determining the ability of a putative inhibitory molecule to inhibit phosphorylated phosphoinositide formation in the cell.
  • Suitable cells include, but are not limited to, mammalian cells. Formation of phosphorylated phosphoinositides can be measured using the method generally described in Ransom et al. (J. Immunol. 137:708-715, 1986).
  • the cells used in a cell-based assay of the present invention are permeabilized prior to contacting the cells with a putative inhibitory compound. Techniques to permeabilize cells for use in an assay of the present invention are known in the art.
  • the present invention also provides methods and kits to identify agents capable of inhibiting or potentiating the various interactions described herein, such as those involving ITIM sequences, of ITIM-activated PTPs. These assays range from simple competitive binding assays, to assays which detect modulation of intracellular signal transduction in a whole cell system.
  • kits kits include: (1) PTPIC protein; (2) a substrate capable of being dephosphorylated by the PTPIC; (3) a means for detecting the dephosphorylation of the substrate; and (4) whereby the ability of a putative regulatory compound to alter the activity of the PTPIC is determined by the detecting means. It is within the skill of one in the art to modify a kit of the present invention to identify regulatory compounds by, for example, adding to the kit appropriate buffers in which to perform a dephosphorylation assay.
  • Suitable substrates for use with a kit of the present invention include, phosphorylated, CD 19, Fyn, Lyn, Blk, Syk, Yes, Lck, Btk, Hck, Src, Zap70, Ig ⁇ , Ig ⁇ , Fc ⁇ RI ⁇ , Fc ⁇ RI ⁇ , Fc ⁇ RIIA, CD3 ⁇ , TCR-zeta, She, PI3 kinase, and/or PLC ⁇ .
  • a suitable means for detecting the dephosphorylation, useful with a kit of the present invention includes the methods of detection generally described in Example 5.
  • the present invention also includes antibodies capable of selectively binding to PTPIC, PTPID, ITIM-pl60 or ITIM-p70. Binding can be measured using a variety of methods known to those skilled in the art including immunoblot assays, immunoprecipitation assays, enzyme immunoassays (e.g., ELISA), radioimmunoassays, immunofluorescent antibody assays and immunoelectron microscopy; see, for example, Sambrook et al., ibid.
  • Antibodies of the present invention can be either polyclonal or monoclonal antibodies.
  • Antibodies of the present invention include functional equivalents such as antibody fragments and genetically-engineered antibodies, including single chain antibodies, that are capable of selectively binding to at least one of the epitopes of the protein or mimetope used to obtain the antibodies.
  • Preferred antibodies are raised in response a peptide comprising a portion of ITIM-pl60 or ITIM-p70 or a fusion protein produced from a nucleic acid molecule encoding full-length ITIM-pl60 or ITIM-p70, or mimetopes thereof.
  • Still another aspect of the present invention relates to the use of such regulatory compounds as described above in the treatment and/or prophylaxis of various hematopoetic disorders.
  • the development of an immune response requires the activation of immune cells by extracellular signals.
  • lymphocyte antigen receptors antigen recognition results in the activation of intracellular protein tyrosine kinases, particularly members of the Src family kinases, as well as the ZAP-70/syk kinases, resulting in increases in tyrosine phosphorylation.
  • signal transduction via the TCR or BCR results in the phosphorylation of critical tyrosines within the cytoplasmic domains of the TCR CD3/ ⁇ chain complex or the a and b chains of the BCR.
  • the critical tyrosines are located in ITAM sequences.
  • phosphoinositide (PI) hydrolysis is initiated leading to elevation of cytoplasmic free calcium which results in B cell proliferation, differentiation, and antibody secretion (D'Ambrosio et al. (1995) Science 268:293).
  • src homology 2 (SH2) domains found on numerous cytosolic signaling molecules mediate direct interaction with tyrosine-phosphorylated protein tyrosine kinases (PTKs) (Songyang and Cantley (1995) TIBS 20:470).
  • the SH2 domain is a globular domain of approximately 100 amino acids that has a pocket that directly binds the phosphotyrosine moiety of phosphopeptides.
  • SH2 domains have been identified for a wide range of molecules which can be divided into two classes.
  • One class contains proteins which contain functional or enzymatic domains such as src family tyrosine kinases, phospholipase C ⁇ , GTPase activating protein, two protein tyrosine phosphatases (PTPIC and PTPID), transcription factor ISGF-3, and the putative GDP-GTP exchanger, Vav.
  • the other class of proteins lack any known catalytic domain and are composed almost exclusively of SH2 and SH3 domains.
  • Members of this group include Crk, GRB2, and Nek.
  • PI3 kinase binds to SH2 domains and may lead to PLC ⁇ translocation to the plasma membrane and its activation.
  • PLC activation results in PI turnover and the production of diacylglycerol and inositol 1 ,4,5-triphosphate (InsP3).
  • IP3 is known to lead to increases in intracellular Ca2+ and result in cell activation, including alterations in gene transcription.
  • IP3 production of IP3 can result in release of intracellular calcium, which can then lead to activation of calmodulin kinase II, which can then lead to serine phosphorylation of a DNA binding protein referred to as ets-1 proto-onco-protein.
  • Diacylglycerol is capable of activating the signal transduction protein, protein kinase C which affects the activity of the API DNA binding protein complex.
  • Signal transduction pathways can lead to transcriptional activation of genes such as c-fos, egr-1, and c-myc.
  • Immune complex-mediated inhibition of antibody production has been shown to depend on coligation of the BCR and the receptor for the Fc region of IgG (Fc ⁇ RIIBl). Mutational analysis of a gene encoding an Fc ⁇ RIIBl has revealed that a 13 amino acid motif in the cytoplasmic domain, is required for negative signaling (Muta et al (1994) Nature 368:70; Amigorena et al (1992), Science 256:1808-1812; and Fridman et al., Immunological Reviews 125:49-76, 1992). This sequence has been termed immune receptor tyrosine-based inhibitor motif (ITIM) (D'Ambrosio et al.
  • ITIM immune receptor tyrosine-based inhibitor motif
  • ITIM motifs have been identified in several receptors, including Ly49, NKIRp58, Fcg receptors, and CD22.
  • An ITIM sequence alignment is shown in Figure 1.
  • SH2 binding ITIMs have been described in the mouse erythropoetin receptor (EPOR), the human IL-2bR, the human IL-3bR, and the c-kit receptor (Thomas (1995) J. Exp Med. 181 :1953).
  • the ITIM motifs present in NKIRp58, Ly49, Fcg receptors, and CD22 which bind to the COOH terminal SH2 domain of PTP
  • the ITIM motifs present in the latter group of receptors bind to the NH2 terminal SH2 domain.
  • Postulated ways by which PTPIC may function include keeping the BCR inactivated before stimulation and/or regulating the threshold with which the BCR responds to antigen (Thomas, supra).
  • Another example of phosphotyrosine mediated recognition is illustrated by the B cell coreceptor, CD19.
  • CD19 is rapidly phosphorylated upon BCR ligation.
  • the phosphorylation of CD 19 on tyrosines 484 and/or 515 initiates the recruitment and activation of PI-3 kinase via the SH2 domains of the PI3 kinase p85 subunit (Tuveson et al (1993) Science 260:986).
  • CD 19 is also a substrate for PTPIC and the dephosphorylation of CD 19 by PTPIC appears to be important in immune cell inhibition.
  • PTP protein tyrosine phosphatase
  • PTPIC protein tyrosine phosphatase
  • PTPID protein tyrosine phosphatase
  • Contemplated substrates include one or more subunits of the receptor (e.g., CD 19, Ig- ⁇ , Ig- ⁇ , Lyn and/or Syk).
  • the PTP could interact with other cellular signaling molecules, such as She or phosphotidylinositol-3 (PI-3) kinase.
  • ITIM-activated PTPIC interacts with and dephosphorylates CD 19. Dephosphorylation of one or more of the foregoing molecules can result in the inactivation of one or more signal transduction pathways that stimulate antibody production by the cell. Accordingly, ITIM mimetics can be used to modulate BCR signaling by altering the enzymatic and localization profile of such phosphatases as PTPIC and PTPID.
  • the present invention also provides for a method of modulating the activation of natural killer cells.
  • NK cells are important in resistance to malignant cells and in certain viral and microbial infections.
  • NK cells express cell surface receptors for MHC class I proteins (NKIRp58 or Ly49, for example). Engagement of these receptors with their ligands leads to a general inhibition of NK cell cytotoxic programs. Similar receptors can be expressed on T cell subsets, and their engagement results in inhibition of different effector functions initiated by stimulation of the CD3/TCR complex. While the human NKIR genes belong to the Ig gene superfamily, the equivalent mouse NKIR belong to a family of dimeric lectins.
  • NK cells are cytotoxic lymphocytes which are capable of inducing the lysis of a variety of target cells.
  • One mechanism by which this is accomplished leads to lysis of antibody-coated target cells via the activation of an antibody-dependent cell cytotoxicity program (ADCC).
  • ADCC antibody-dependent cell cytotoxicity program
  • the induction of natural cytotoxicity programs involves lysis of target cells which either do not express, or express in a modified form, MHC class I molecules (Yokoyama, W. M. 1995. Cur. Opinion Immunol. 7:110; Raulet, D. H., and W. Held. 1995. Cell 82: 697; Gumprez, J. E., and P. Parham. 1995. Nature 378: 245).
  • ADCC the engagement of the multimeric CD 16 receptor complex activates protein tyrosine kinase (PTK)-dependent pathways leading to the tyrosine phosphorylation of ITAM (immunoreceptor tyrosine-based activation motif) expressed in CD3z and/or FceRIg
  • PTK protein tyrosine kinase
  • SH2-tandem PTK such as ZAP-70 and p72Syk
  • SH2-tandem PTK such as ZAP-70 and p72Syk
  • NKIR family of MHC class I -specific receptors capable of inhibiting NK cell activation has been described both in human and in mouse (Karlhofer et al. 1992. Nature 358: 66; Moretta et al. 1993. J.
  • Human NKIR belong to the Ig superfamily and are characterized, in their extracellular portions by two or three Ig-like domains, corresponding to HLA-C-specific p58 and HLA-B-specific p70/NKBl receptors respectively (Wagtmann et al. 1995. Immunity 2:439; Colonna, M., and J. Samaridis. 1995. Science 268:405; D' Andrea et al. 1995. J. Immunol. 155:2306).
  • the intracytoplasmic tail is 76-84 amino-acid long, is highly conserved (73% amino-acid identity between human NKIR members), and contains two (I/V)xYxxL stretches originally described as ITAM-like. The integrity of this intracytoplasmic sequence appears to be critical for NKIR-mediated inhibition. Indeed, a naturally-occurring form of the molecule, truncated 2 amino-acid carboxy-terminal of the first Y residue, mediates NK cell activation rather than inhibition.
  • FcgRIIBl ITIM can inhibit cell triggering mediated via the CD3/TCR as well as the FceRI complexes (Daeron et al. 1995. Immunity 3:1).
  • the molecular dissection of FcgRIIB 1 -induced inhibition revealed that the Y309 residue of mouse FcgRIIBl ITIM is phosphorylated upon BCR-Fc ⁇ RIIBl co-engagement, and recruits several proteins, including PTPIC (D'Ambrosio et al. 1995. Science 268:293).
  • the PTPase PTPIC (HCP, SHP, SH-PTP1) is a hematopoietic specific-PTPase expressing two tandem SH2 domains linked to a C-terminal catalytic domain (Stone, R. L., and J. E. Dixon. 1994. J. Biol. Chem. 269:31323).
  • PTPIC is involved in many inhibitory signaling pathways, such as the termination of erythropoietin receptor as well as Kit/SCF receptor signals.
  • the B cell surface molecule CD22 contains 3 I/VxYxxL stretches which can bind PTPIC upon tyrosine phosphorylation, and regulates B cell activation programs (Doody et al. 1995.
  • one embodiment of the present invention includes a cellular system where an activating receptor is coligated with a negative regulatory receptor, for example an Fc ⁇ RII is co-ligated with a B cell receptor which is regulated by the Fc ⁇ RII.
  • the cell is then contacted with a regulatory reagent capable of binding to a protein including PTPIC, PTPID, ITIM-pl60 and ITIM-p70.
  • the Fc ⁇ RII contains the amino acid sequence TAENTITYSLLKH, GAENTITYSLLMH, preferably in which the tyrosine residue is phosphorylated.
  • the Fc ⁇ RII contains the amino acid sequence ITYSLL, and even more preferably IXYXXL, preferably the tyrosine residue is phosphorylated.
  • they reagent comprises the core sequence ((I V)XYXX(L/V), in more preferred embodiments the tyrosine residue is phosphorylated.
  • another embodiment of the present invention includes a method to regulate antibody production, comprising contacting a cell, having a receptor selected from the group consisting of a B cell receptor, an Fc ⁇ RIII, an Fc ⁇ RI and/or an Fc ⁇ RII, with an effective amount of a regulatory reagent that is capable of binding to a protein including PTPIC, PTPID, ITIM-pl60 and ITIM-p70, in which the protein is capable of altering the biological response resulting from the co-ligation of a combination of receptors selected from the group consisting of a B cell receptor and an Fc ⁇ RII, an Fc ⁇ RI and an Fc ⁇ RII, and an Fc ⁇ RIII and an Fc ⁇ RII, thereby resulting in the modulation of antibody production, and/or proliferation.
  • the present method is particularly useful for protecting an animal from diseases such as allergic responses and autoimmune diseases. If antibody production is stimulated, the present method is particularly useful for protecting an animal from diseases such as AIDs and diseases against which an animal can be immunized (i.e., diseases caused by an infectious agent).
  • a separate aspect of the present invention relates to the recognition that one can regulate the activity of a signal transduction molecule in a cell by contacting a cell with a regulatory reagent of the present invention.
  • a method for regulating hematopoietic cell function comprises contacting a cell with an effective amount of a regulatory reagent of the present invention that is capable of binding to a protein selected from the group consisting of PTPIC, PTPID, ITIM-pl60 and ITIM-p70, in such a manner that the activity of the protein is altered (e.g., inhibited or stimulated) resulting in regulation of hematopoietic cell function.
  • a method for regulating hematopoietic cell function comprises contacting a cell with an effective amount of a regulatory reagent of the present invention that is capable of altering the concentration of a molecule selected from the group consisting of PTPIC, PTPID, ITIM-pl60 and ITIM-p70 in the cell, thereby resulting in the regulation of hematopoietic cell function
  • an "ITIM mimetic” refers to an agent capable of agonizing or antagonizing a signal transduction activity mediated by an ITIM sequence of a receptor.
  • the ITIM peptides and peptidomimetics described above are of course ITIM mimetic, as are agents discovered in the drug screening assays described above.
  • other SH2 binding agents described in the art while perhaps not as optimal as the subject ITIM peptides for, e.g., activating PTPIC or PTPID, may nevertheless be used to modulate ITIM-dependent activities.
  • the ITIM mimetic can be similar to the phosphotyrosine benzodiazepine peptidomimetics described in PCT application WO 95/251 18 to Bachovchin, and the phosphotyrosine peptides described the PCT application WO 94/08600 to Shoelson. both of these publications describe tetra peptides corresponding to pYXXL, e.g. not including amino acid residues in the -2 position as our data suggest. Nevertheless, such other phosphotyrosinecontaining peptides may be capable of interacting with PTPIC, PTPID, ITIMpl ⁇ O, ITIM p70, and/or other cellular targets with which a native ITIM interacts.
  • ITIM mimetics may mimic the PTP activation of a native ITIM, or may be agonistic (e.g. inhibitory) of that activation by competitively binding to the PTPIC SH2 domain yet failing to allosterically activate the phosphatase.
  • an ITIM mimetic can be contacted with a cell, either in vivo (e.g. adminstered to a patient or animal) or in vitro (e.g. employed in cell culture), to affect the responsiveness of a hematopoetic cell to a growth factor, cytokine or other receptor ligand; to modulate proliferation, influence differentiation of cells, or modulate effector functions of cells, such as antibody production, antibody dependent cellular cytotoxicity, cytokine secretion, secretion of other soluble mediators (including preformed mediators), or cytolysis among others.
  • the subject compound modulates the signal transducing ability of an protein having an enzymatic activity.
  • Exemplary enzymes include cytoplasmic tyrosine kinases (eg. Src, Lck), phosphotyrosine phosphatases, phospholipase C ⁇ (PLC ⁇ ) and the like.
  • cytoplasmic tyrosine kinases eg. Src, Lck
  • phosphotyrosine phosphatases eg. PLC ⁇
  • PLC ⁇ phospholipase C ⁇
  • the subject compounds may also be utilized as part of therapeutic regimens for the treatment of a variety of IgE mediated diseases, such as inflammatory and allergic reactions implicating degranulation of basophils and mast cells.
  • IgE mediated diseases such as inflammatory and allergic reactions implicating degranulation of basophils and mast cells.
  • the compounds of the present invention can be used to control chronic allergic inflammation, as well as in the treatment of asthma.
  • the immediate-type hypersensitivities such as anaphylaxis, allergic rhinnitis, atopic dermatitis, asthma, allergic bronchopulmonary aspergillosis, hepersensitivity pneumonitis, extrinsic asthma, hay fever, and allergic responses to certain foods or drugs, are mediated primarily by one of the immunoglobulin isotypes, i.e., IgE.
  • IgE immunoglobulin isotypes
  • the allergen binds to the IgE which is bound to receptors (e.g., MIRRs) on the surface of mast cells and basophilic leukocytes (basophils).
  • the binding of the allergen causes crosslinking of the surface IgE molecules and hence the underlying receptors for the Fc portion of IgE (Fc ⁇ R), thereby triggering cellular degranulation with the release of pharmacologic mediators such as histamine, neutral proteases (e.g. tryptases, chymotryptase, carboxypeptidase), LTC4, LTB4, PGD2, TXA2, PAF, cytokines (e.g. IL-4 or TNF ⁇ ), the slow-reacting substance of anaphylaxis (SRA), and serotonin.
  • pharmacologic mediators such as histamine, neutral proteases (e.g. tryptases, chymotryptase, carboxypeptidase), LTC4, LTB4, PGD2, TXA2, PAF, cytokines (e.g. IL-4 or TNF ⁇ ), the slow-reacting substance of anaphylaxis (SRA), and seroton
  • Another embodiment of the present invention is includes a method to regulate the release and/or production of mast cell or basophil mediators such as, histamine, IL-5 and/or IL-8, or other mediators of hypersensitivity responses comprising contacting a basophil or mast cell with an effective amount of a regulatory reagent that is capable of binding to a protein including PTPIC, PTPID, ITIM-pl60 and ITIM-p70, in which the protein is capable of altering the biological response resulting from the co-ligation of an Fc ⁇ RIII and/or an Fc ⁇ RI with an Fc ⁇ RII, thereby resulting in the inhibition of histamine, IL-5 and/or IL-8 production or release.
  • a regulatory reagent that is capable of binding to a protein including PTPIC, PTPID, ITIM-pl60 and ITIM-p70, in which the protein is capable of altering the biological response resulting from the co-ligation of an Fc ⁇ RIII and/or an Fc ⁇ RI with an Fc ⁇
  • the step of regulating includes stimulating or inhibiting IL-5 or IL-8 production, and inhibiting histamine production. If histamine or cytokine production is inhibited, the present method is particularly useful for protecting an animal from allergic or other immune responses. If IL-5 is stimulated, the present method is particularly useful for treatment of diseases in which antibody production is needed, such as in protection of an animal from immunodeficiency diseases or infectious diseases.
  • Yet another embodiment of the present invention features the use of an anatagnostic ITIM mimetic, or other agent which inhibits the inactivating phosphatase PTPIC or PTPID, as an adjuvant.
  • an anatagnostic ITIM mimetic or other agent which inhibits the inactivating phosphatase PTPIC or PTPID, as an adjuvant.
  • PTPIC to downregulate antigen-induced signaling in lymphocytes
  • ITIM peptides which bind to PTPIC but which fail to activate the phosphatase or inhibit its localization may be useful adjuvants.
  • compounds which inhibit the phosphatase activity directly such as which may be discovered in the assays set out above, may also serve as adjuvants.
  • these adjuvants may also be use to enhance immunoresponsiveness in the treatment of a variety of immunodeficiencies.
  • the invention also relates to agents which can be utilized as part of therapeutic regimens for the treatment of a variety of IgE mediated diseases, such as inflammatory and allergic reactions implicating degranulation of basophils and mast cells.
  • IgE mediated diseases such as inflammatory and allergic reactions implicating degranulation of basophils and mast cells.
  • the present invention provides for ITIM peptides or nucleic acids, in particular ITIM pharmaceutical preparations which are capable of modulating the activation of basophils and or mast cells by modulating Fc ⁇ R signaling.
  • the subject invention provides bispecific antibodies for cross-linking Fc ⁇ receptors (Fc ⁇ R) with Fc ⁇ R in order to inhibit signaling from Fc ⁇ R engaged by IgE.
  • the bispecific antibodies of the present invention can be used to control chronic allergic inflammation, as well as in the treatment of asthma.
  • the immediate-type hypersensitivities such as atopic dermatitis, extrinsic asthma, hay fever, and allergic responses to certain foods or drugs, are mediated primarily by one of the immunoglobulin isotypes, i.e., IgE.
  • IgE immunoglobulin isotypes
  • the allergen binds to the IgE which is bound to receptors (e.g., MIRRs) on the surface of mast cells and basophilic leukocytes (basophils).
  • the binding of the allergen causes crosslinking of the surface IgE molecules and hence the underlying receptors for the Fc portion of IgE (Fc ⁇ R), thereby triggering cellular degranulation with the release of pharmacologic mediators such as histamine, the slow-reacting substance of anaphylaxis (SRA), and serotonin.
  • pharmacologic mediators such as histamine, the slow-reacting substance of anaphylaxis (SRA), and serotonin.
  • SRA slow-reacting substance of anaphylaxis
  • Antigen-mediated aggregation of the high-affinity receptor for immunoglobulin E, Fc ⁇ RI results in the activation of multiple signaling pathways, leading to the release of mediators of the allergic response.
  • coligation of the Fc ⁇ RI with Fc ⁇ R results in down regulation of Fc ⁇ R signal transduction.
  • recruitment of PTPs, such as PTPIC by the coligated Fc ⁇ R may cause dephosphorylation of the ITAM motif tyrosines in the ⁇ and ⁇ subunits of Fc ⁇ RI and thereby antagonize association of the tyrosine kinase Syk with the phosphorylated receptor or may block Fc ⁇ R signaling by inhibiting PBKinase activation by a CD 19 analog.
  • the former association is mediated by the SH2 domains of Syk and is believed to be critical for activating signaling pathways resulting in mediator release. Accordingly, disruption of the Fc ⁇ R-mediated signal pathway by a compound of the present invention can provide for prophylaxis and or direct treatment of diseases or injuries implicating degranulation of such cells.
  • the subject compounds can further be used in the treatment of, for example, allergic lesions by selective modulation of signal transduction pathways induced by cytokines.
  • Antibodies in vivo are bivalent and monospecific, containing two identical antigen binding sites.
  • the specific binding of antigen by an antibody molecule is determined by the antibody's structure of the variable regions (Fab) of both heavy and light chains.
  • Antibodies having dual specificities have been prepared by subjecting antibodies of different specificities to a selective cleavage of the disulfide bridges that link the two heavy chains together. Antibody half-molecules are then reassociated under neutral pH to produce the hybrid antibodies having dual specificities.
  • Such approaches can be employed to make a bispecific antibody which is capable of crosslinking the Fc ⁇ R and Fc ⁇ R.
  • Nisonhoff et al., (1962) Nature 194:355 describe one applicable method for the in vitro production of a bispecific antibody molecule.
  • the monospecific anti-Fc ⁇ R and anti-Fc ⁇ R antibodies are treated with pepsin to remove the Fc portion of each antibody, leaving two antigen-binding sites (Fab) covalently linked by a single disulfide bond. This bond is then split under reducing conditions and two antibody fragment pools combined and reassociated together under oxidizing conditions to produce a bispecific antibody.
  • Fab antigen-binding sites
  • anti-Fc ⁇ R and anti-Fc ⁇ R antibodies can be covalently linked.
  • the anti-Fc ⁇ R and anti-Fc ⁇ R antibodies are first reacted with N-suc-cinimidyl-3-(2- pyridyldithio) propionate (SPDP). Thiol groups are attached to the cleaved anti-Fc ⁇ R antibody using 2-iminothiolane. Then the two modified half-antibodies, anti-Fc ⁇ R and anti- Fc ⁇ R, are mixed to covalently link the two antibodies.
  • SPDP N-suc-cinimidyl-3-(2- pyridyldithio) propionate
  • the ⁇ anti-Fc ⁇ R x anti-Fc ⁇ R ⁇ bispecific antibodies of the present invention can be produced from hybridomas.
  • the preparation of bispecific monoclonal antibodies by fusion of antibody-producing hybridoma cells is described in Milstein and Cuello, (1983) N ⁇ twre 305:537 and PCT application, WO83/03679.
  • two hybridomas expressing anti-Fc ⁇ R and anti-Fc ⁇ R antibodies respectively
  • hybrid hybridomas secrete can be selected for those which produce predefined bispecific monoclonal antibodies.
  • the bispecific monoclonal antibodies produced by hybrid hybridomas are complete molecules, containing the Fc region as well as the antigen-combining sites.
  • Example 1 This example describes the identification of PTPIC, ITIM-pl60 and ITIM-p70 as ITIM binding molecules in co-precipitation studies.
  • ITIM peptide ⁇ on-phosphorylated (ITIM peptide) and tyrosine phosphorylated murine ITIM peptides (pITIM) having the sequences TAENTITYSLLKH and TAENTIT(p)YSLLKH, respectively, were synthesized by Macromolecular Resources, Inc. (Ft. Collins, CO).
  • A20 B lymphoma cells were loaded with [ 35 S]-Methionine using the method generally described in Cold Spring Harbor Labs Press, 1989 Harlow and Lane, Antibodies: A Laboratory Manual. Cold Spring Harbor Press, 1988.
  • the [ 35 S]-Methionine A20 cells were o used to prepare several different samples. The first sample included 1 x 10 per ml unstimulated A20 cells.
  • the second sample included 1 x 10 per ml A20 cells stimulated with intact (80 ⁇ g/ml) rabbit anti-mlg antibodies (Zymed, San Franscisco, CA) for 2 min at 37°C.
  • the third sample included 1 x 10 8 per ml A20 cells stimulated with F(ab')2 (50 ⁇ g/ml) of the rabbit anti-mlg antibodies.
  • the cells in the samples were immediately lysed in 1% NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 2.0 mM Sodium Orthovanadate, 10 mM Sodium pyrophosphate, 0.4 mM EDTA, 10 mM NaF, 1 mM Phenylmethylsulfonyl fluoride, and 2 ⁇ g/ml each of aprotinin, leupeptin, and a-1-antitrypsin).
  • Peptide adsorbates were produced by incubating separate 0.4 ml of postnuclear 1% NP-40 lysates of unstimulated, intact or F(ab')2 rabbit anti-mlg antibody-stimulated [ S]- Methionine labeled A20 cells (20 x 10 cells per sample) with either ITIM and pITIM peptide (20 ⁇ g) coupled Sepharose beads (10 ⁇ l of 50% slurry) (Pharmacia, Piscataway, NJ) for 1 hr at 4°C. The absorbed material was eluted with 2.2% formic acid (0.1 ml) which was subsequently eliminated by lyophilization. The peptide adsorbates were boiled for 5 min in SDS reducing sample buffer and fractionated by 10% SDS-PAGE. Any [ 35 S]-Methionine eluted from the peptide-bound beads were identified by autoradiography.
  • the relative molecular weights of the proteins were 160. 70 and 65 kDa.
  • the protein having a molecular weight of 160 is referred to herein as ITIM- pl60.
  • the protein having a molecular weight of 70 is referred to herein as ITIM-p70.
  • Example 2 This example describes the amino acid sequencing of the tyrosine phosphorylated pITIM-binding 65 kDa protein.
  • Samples of the three pITIM-binding proteins described in Example 1 were isolated from NP-40 lysates of 5 x 10 A20 cells by incubating the lysate with 100 ⁇ g pITIM peptide and eluting any peptide-bound protein using 50 mM (100 ⁇ l) p-NPP (a phosphotyrosine analog). The eluted proteins were resolved on a 10% SDS-PAGE gel and the 65 kDa band was transferred onto Immobilon-P membrane (Millipore Co ⁇ ., Bedford, MA). The proteins isolated on the membrane were subjected to N-terminal sequence analysis using a PROCISE Applied Biosystems amino acid sequencer (Applied Biosystems, CA). The N-terminal 17 amino acid sequence was found to be a perfect match for the phosphotyrosine phosphatase PTPIC (also known as HCP or SH-PTP1).
  • Example 3 This example describes immunoblot experiments using antibodies specific for PTPIC to confirm the amino acid sequencing data.
  • pITIM peptide adsorbates were prepared as described in Example 1. The adsorbates were resolved by SDS-PAGE and the proteins were electrophoretically transferred to Immobilon-P membranes.
  • Anti-PTPIC antibodies were prepared by immunizing rabbits with the N-terminal portion of PTPIC protein cleaved from a bacterially expressed GST fusion protein (residues 1 to 193). The polyclonal antiserum was used to probe the membrane containing the transferred protein using techniques standard in the art. The resulting immunoblots were developed with an enhanced chemiluminescence (ECL) detection system (Amersham, Buckinghamshire, England).
  • ECL enhanced chemiluminescence
  • a protein having the molecular weight of 65 kDa was identified using the anti-PTPlC antiserum.
  • equal amounts of PTPIC were present in pITIM peptide adsorbates of whole and F(ab')2 rabbit anti-mlg stimulated and unstimulated A20 cells, thus indicating that PTPIC association the pITIM peptide does not require receptor mediated modification of the PTPIC enzyme.
  • Example 4 This example describes the identification of PTPIC binding to Fc ⁇ RIIBl in vivo.
  • Fc ⁇ RIIBl was immunoprecipitated from 0.1 ml of postnuclear 1% NP-40 lysates of unstimulated, intact or F(ab')2 rabbit anti-mlg antibody stimulated A20 cells (50 x 10 /sample) by incubating the lysates with 2.4G2 (30 ⁇ g) coated Sepharose beads (25 ⁇ l of 50% slurry) for 15 min at 4°C.
  • the immunoprecipitated proteins were resolved by SDS- PAGE and transferred to blotting paper using the methods described in Example 2.
  • the blotting paper was sequentially immunoblotted with 1 :1000 dilution of ascites containing anti-Fc ⁇ RIIB antibody, 1 :1000 dilution of anti-phosphotyrosine antibody (Ab2, Oncogene Science, Uniondale, NY), and 1 :1000 dilution of anti-PTPIC antiserum.
  • the immunoblotting results obtained using the anti-phosphotyrosine antibody indicated that Fc ⁇ RIIB 1 is tyrosine phosphorylation upon stimulation of the A20 with intact anti-mlg antibodies. No tyrosine phosphorylation stimulation was detected in the unstimulated cells or in those cells incubated with F(ab')2 anti-mlg antibody.
  • Immunoblotting results obtained using the anti-Fc ⁇ RIIB antibody indicated that stimulation of the A20 cells with intact anti-mlg antibody had no effect on the levels of Fc ⁇ RIIB 1 in the immunoprecipitations.
  • Bacterial ly expressed GST fusion proteins of PTPIC amino or carboxyl SH2 domain were incubated with lysates of unstimulated, whole and F(ab')2 anti-mlg stimulated A20 cells prepared according to the method described in Example 1. Proteins contained in the PTP 1 C fusion protein adsorbates were resolved by SDS-PAGE and transferred to blotting paper as described in Example 2. The blotting paper was immunoblotted with the anti-phosphotyrosine and anti-Fc ⁇ RIIB 1 antibodies as described in Example 3.
  • Peptide adsorbates were prepared as described in Example 1 by incubating 20 ⁇ g PTPIC amino- or carboxyl SH2 domain fusion protein were precipitated with 5 ⁇ g pITIM peptide coupled Sepharose beads. Proteins contained in the peptide adsorbates were resolved by SDS-PAGE and the gel was stained with Comassie Blue.
  • PTPIC was isolated by incubating 1% NP-40 lysates (lacking Sodium Orthovanadate and Sodium pyrophosphate) of unstimulated A20 cells (2 x 10 ) with 250 ⁇ g pITIM coated Sepharose beads (100 ⁇ l of 50% slurry) using the methods described in Example 1. After incubation for 1 hr at 40°C, the peptide-coated beads were washed twice in 1% NP-40 lysis buffer and once in phosphatase buffer (10 mM Imidazole (pH 7.0), 50 mM EDTA, 0.1% 2- mercaptoethanol, 1 mg/ml bovine serum albumin).
  • the pITIM bound PTPIC was eluted with 300 ⁇ l of 50 ⁇ M p-NPP in phosphatase buffer.
  • the p-NPP was eliminated from the eluent by dialysis by centrifugation in a Microcon 10 tube (Amicon, Beverly, MA) in 30x volume of phosphatase buffer for 30 minutes at 4°C.
  • a peptide having the sequence RRLIEDNEYTARQGA was obtained from Macromolecular Resources, Inc. which contains an autophosphorylation site.
  • the Fyn peptide was phosphorylated at the tyrosine residue using [ ? PJ-ATP and the B subunit if the
  • dephosphorylation of the Fyn peptide was performed at 30°C for 15 minutes in the presence of 20 ⁇ l of the eluted PTPIC and 30,000 cpm of [ 32 P]-ATP-labelled Fyn peptide in a final volume of 40 ⁇ l.
  • the assay was performed in the absence or presence of various amounts on ITIM peptide, pITIM peptide, tyrosine phosphorylated Ig- ⁇ (ENL(p)YEGLNLDDCSM(p)YEDI) and Fc ⁇ RI- ⁇ ITAM peptides
  • This example describes the correlation of Fc ⁇ RIIB 1 inhibitory function with tyrosine phosphorylation of the Fc ⁇ RIIB 1 ITIM and association with PTPIC in vivo using a mutated Fc ⁇ RIIB 1 which lacks the ITIM tyrosine.
  • Expression vectors encoding Fc ⁇ RIIB 1 truncated at amino acid residue 314 and containing the wild type ITIM (CT314 WT) and Fc ⁇ RIIBl truncated at amino acid residue 314 in which the tyrosine 309 of the ITIM was substituted with alanine (CT314 Y309-A) were transformed into IIA1.6 cells (generally described in Jones et al., J. Immunol. 136:348- 352, 1986) and are referred to herein as CT314 WT-IIA1.6 cells and CT314 Y309-A-IIA1.6 cells, respectively.
  • CT314 WT and CT314 Y309-A encoded receptor on the surface of their respective cell lines were confirmed as follows. About 1 x 10 CT314 WT-IIA1.6 cells or CT314 Y309-A-IIA1.6 cells were stained with biotinylated 2.4G2 antibody and fluoresceinated avidin (Tago Inc., Burlingame, CA) or with fluoresceinated avidin only and analyzed by flow cytometry (F AC Scan, Becton Dickinson. Richmond, CA) as described in Justement et al., J. Immunol. 143:881-886, 1989). The results indicated that CT314 WT- II A 1.6 cells expressed CT314 WT encoded increased receptor numbers over background and CT314 Y309-A -IIA1.6 cells expressed CT314 Y309-A encoded increased receptor number over background.
  • CT314 WT and CT314 Y309-A encoded receptors were assessed. 1 x 10 CT314 WT-IIA1.6 cells and CT314 Y309-A -IIA1.6 were loaded with 5 ⁇ M Indo-1 AM (Molecular Probes, Eugene, WA) using methods described in Justement et al., ibid.
  • Indo-1 AM Molecular Probes, Eugene, WA
  • A-IIA1.6 cells showed similar late phase Ca mobilization following stimulation with whole or F(ab')2 anti-mlg antibodies, thus indicating that the tyrosine of the ITIM is essential for inhibition of Ca mobilization.
  • a modest inhibition of Ca mobilization was detectable in response to BCR co-ligation with the CT314-Y309-A mutant Fc ⁇ RIIB 1 indicating that other regions within the cytoplasmic domain may play a role in Fc ⁇ RIIBl mediated negative signaling.
  • Fc ⁇ RIIB 1 were immunoprecipitated from unstimulated, intact (80 ⁇ g/ml) or F(ab')2 (50 ⁇ g/ml) stimulated IIA1.6 transfected cells (50 x 10 /samples) using methods described in Example 2. Immunoprecipitated material was collected by formic acid elution as described in Example 2 and after boiling for 5 min in SDS reducing sample buffer, fractionated by 10% SDS-PAGE, electrophoretically transferred to Immobilon-P and subjected to sequential immunoblotting with anti-phosphotyrosine antibody and anti-Fc ⁇ RIIB 1 antibody. Immunoblots were developed with ECL detection system (Amersham).
  • CT314 WT isolated from cells stimulated with whole anti- mlg antibodies were tyrosine phosphorylated and bound PTPIC protein.
  • CT314 Y309-A receptor was not phosphorylated and did not bind PTPIC following BCR co- ligation.
  • Example 8 This example describes Fc ⁇ RI mediated signaling and PTPIC expression in rat basophilic leukemia cells.
  • Rat Basophilic Leukemia (RBL) cells that express endogenous Fc ⁇ receptor (Fc ⁇ RI) were transformed with an expression vector encoding Fc ⁇ RIIB.
  • Expression of PTPIC in the transformed RBL cells was determined by immunoblotting of whole cell lysates using anti- PTP1C antiserum. The immunoblot results indicated that the transformed RBL cells expressed comparable amounts of PTPIC as A20 B cells.
  • K46 ⁇ B lymphoma cells (4 x 107ml) were stimulated with 50 ⁇ g/ml monoclonal anti-IgM antibody (b-7-6) at 37°C for 3 minutes.
  • RBL cells (1 x 10 /ml) were incubated overnight with DNP-specific IgE antibody and DNP-BSA antigen (20 ng/ml) for 3 minutes at 37°C.
  • Clarified 1% NP-40 lysates of stimulated or nonstimulated cells were prepared (1 x 10 cell equivalents for K46 ⁇ ; 5 x 10 cell equivalents for RBL) and fractionated by SDS-PAGE under reducing conditions.
  • Proteins were transferred to Immobilon, probed by immunoblot analysis using anti-phosphotyrosine specific antibodies and visualized using the ECL method.
  • the immunoblot results indicate that the transformed RBL cells exhibit protein tyrosine phosphorylation and responses upon Fc ⁇ RI aggregation using rat IgE anti-DNP antibodies and DNP-BSA antigen.
  • Example 9 shows that human and mouse natural killer cell inhibitory receptors recruit the PTPIC and PTPID protein tyrosine phosphatases.
  • Ly49A has been shown to directly interact with H-2D ⁇ and H-2D ⁇
  • CD3 ⁇ l YQ64QGQNQLY71NELNLGRREEY82DVLDKRRGR91
  • the phosphorylated CD3 ⁇ l, Fc ⁇ RIg, p58.183.1 and p58.183.2 peptides were obtained from Neosystem (France) and synthetized with a N-terminal biotin. Unphosphorylated peptides were synthetized by P. Fourquet at the Centre d'lmmunologie de Marseille-Luminy, and were obtained as N-terminal biotinylated (NHS-LC-biotin, Pierce) or not. Biotinylated peptides were coupled to streptavidin-agarose beads (Sigma), and Ly49 peptides were coupled to CnBr-sepharose beads (Pharmacia) as recommended by the manufacturers.
  • Biotinylated peptides (2 ng) were immobilized on streptavidin microchips, and their immobilization was confirmed by the binding of an anti-phosphotyrosine mAb (4G10, UBI).
  • Cells and cell lysates CD3/TCR + T cells expressing p58.183 NKIR were isolated from peripheral blood lymphocytes and cultured in the presence of recombinant IL-2 (lOOU/ml) as previously described (12).
  • the human NK cell lines NK3.3 Kernbluth et al. 1982. J. Immunol. 129:2831
  • NKL Kerman et al. 1995. Proc. Natl. Acad. Sci.
  • Biotinylated peptides (5 mg ml) were coupled to streptavidin-agarose beads for 1 hour at 4°C (Sigma), prior to bead saturation with D-biotin (1 mg/ml) for 1 hour at 4°C (Sigma). After 3 washes in lysis buffer, samples were combined with reducing sample buffer (New England Biolabs) and boiled, before separation on SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Anti-PTPIC (0.5 mg/ml) and anti-PTPID (0.1 mg/ml) mAb were purchased form Transduction laboratories. Immunoblots were revealed using horseradish peroxidase-conjugated rabbit anti-mouse antiserum (Sigma) and ECL detection system (Amersham).
  • RBL cells were kindly obtained from Dr. Marc Daeron (Institut Curie, Paris) (Daeron et al. 1995. Immunity 3: 1). RBL cells were transfected by electroporation using the 183.6 cDNA encoding p58.183, in the RSV-5.gpt expression vector (Wagtmann et al. 1995. Immunity 2:439). Stable transfectants were established by culture in the presence of xanthine (250 mg/ml), hypoxanthine (13.6 mg/ml) and mycophenolic acid (2 mg/ml). The cell surface expression of p58.183 was confirmed by immunofluorescence and flow cytometric analysis.
  • Cells from a representative clone were stimulated for 3 minutes at 37°C in the presence or absence of 150 mM sodium pervanadate. Cells were then instantly lysed at 4°C in NP-40 lysis buffer, and immunoprecipitations were carried out using 10 mg/ml anti-CD3e or anti-GL183 mAb, and protein G sepharose beads (Pharmacia).
  • PTP1C/PTP1D Binding PTPIC binding to phosphorylated p58.183 peptides was tested in human T and NK cell lysates. NK3.3 cells were lysed in NP-40 lysis buffer and adsorbed with unphosphorylated p58.183.1 as well as phosphorylated p58.183.1 and p58.183.2 peptides coupled to streptavidin-agarose beads. Affinity-bound proteins were resolved on 10% SDS-PAGE, transferred to nitrocellulose and probed with anti-PTPIC and anti-PTPID mAb.
  • NKL cells (15 X 10 ⁇ cells/sample) were prepared as described above and adsorbed with phosphorylated p58.183.1, p58.183.2 and CD3z.l peptides bound to beads. The immunoblot was probed with anti-PTPIC mAb.
  • p58 + T lymphocytes were prepared as described above and adsorbed with phosphorylated p58.183.1 and CD3 ⁇ .l peptides bound to beads or directly resolved on SDS-PAGE. The immunoblot was probed with anti-PTPIC mAb.
  • RBL cells expressing the p58.183 molecule were stimulated or not with sodium pervanadate.
  • NP-40-lysates were prepared and directly resolved on 8% SDS-PAGE under non-reducing conditions, or immunoprecipitated using anti-CD3 ⁇ (UCHT1 , IgGl) or anti-p58.183 (GL183, IgGl) mAb. The immunoblot was probed with anti-PTPIC mAb.
  • NP-40 lysates from A20 murine B lymphoma cells were adsorbed with either Ly49- or phosphorylated Ly49-beads. Samples were analyzed on SDS-PAGE and revealed with polyclonal rabbit anti-PTPIC and anti-PTPID antibodies. WCL are whole cell lysates. Binding was inhibited by addition of 50 mM -nitrophenyl phosphate (pNPP), a phosphotyrosine analog, to the lysates during adso ⁇ tion.
  • pNPP mM -nitrophenyl phosphate
  • A20 cell lysates were prepared as described above, and adso ⁇ tion was performed using unphosphorylated or phosphorylated FcgRIIBl ITIM peptides. Samples were analyzed on SDS-PAGE and revealed with polyclonal rabbit anti-PTPIC and anti-PTPID antibodies. Binding was inhibited by addition of 50 mM pNPP to the lysates during adso ⁇ tion.
  • NP-40 lysates were also prepared from Jurkat human T leukemia cells. Samples were resolved on 10% SDS-PAGE, transferred to nitrocellulose and probed respectively with anti- PTPIC and PTPID mAbs.
  • NKIR molecules contain two independent ITIM sequences
  • unphosphorylated and phosphorylated peptides surrounding the N-terminal Y303 (p58.183.1 peptide) and the C-terminal Y333 (p58.183.2 peptide) residues of p58.183 intracytoplasmic sequence were synthesized. These peptides were coupled to beads, and then used to adsorb lysates prepared from two distinct human NK cell lines, NK3.3 and NKL, as well as human p58.183 + T cell lysates, prior to immunoblotting using anti-PTPIC mAb. Each of the phosphorylated p58.183 peptides bind the PTPIC PTPase expressed in these cells.
  • PTPID Syp, PTP2C, SH-PTP2
  • csw Drosophilia homologue corkscrew
  • PTPID is ubiquitously expressed and regulates PTK-dependent signaling mechanisms (Stone, R. L., and J. E. Dixon. 1994. J. Biol. Chem. 269:31323). Therefore, NK cell lysates adsorbed with unphosphorylated and phosphorylated p58.183 peptides were also probed for the binding of PTPID. Each of the phosphorylated p58.183 peptides bind PTPID, whereas no binding to unphosphorylated p58.183.1 was detected.
  • the human NKIR p58 has been shown to be part of a multimeric non-covalent complex including FceRIg and CD3z (Bottino et al. 1994. Eur. J. Immunol. 24:2527). No binding of PTPIC and PTPID to double tyrosine-phosphorylated CD3z.l and FceRIg ITAM peptides can be detected, emphasizing the specificity of PTPases recruitment by tyrosine-phosphorylated human NKIR. Of note, no binding of other SH2-containing proteins, such as p56 ⁇ c ⁇ and p5 V M was detected under similar peptide adso ⁇ tion and immunoblotting conditions (data not shown).
  • the IC50 of phosphorylated Ly49A for competing phosphorylated p58.183.1 binding to PTPIC is in the same order of magnitude that the IC50 of phosphorylated p58.183.2 (Table 2), confirming that phosphorylated Ly49A does bind to PTPIC.
  • IC 50 were defined as the concentration of competitor ligand required to achieve a 50% reduction in the binding of GST-PTP1C-SH2 (N+C) to an immobilized phosphorylated p58.183.1 peptide.
  • IC 50 were calculated from competition assays using SPR: GST-PTP1C- SH2 (N+C) at 500 nM was preincubated with various concentrations (0 to 100 mM) of indicated free peptides, and injected over immobilized phosphorylated p58.183.1 surface.
  • I/VxYxxL/V motifs expressed in both human and mouse NKIR intracytoplasmic domains can be defined as ITIM.
  • phosphorylated human NKIR and FcgRIIBl ITIM preferentially recruit PTPIC
  • our data indicate that the phosphorylated mouse NKIR ITIM binds PTPID with a higher affinity than PTPIC.
  • JAK Janus PTK
  • JAK3 / '" mutant mice lack NK cells and PTPIC is involved in the down-regulation of JAK1, JAK2 and TYK2 function (Park et al 1995. / mmunity 3:771 ; Yetter et al. 1995. J. Biol. Chem. 270:18179).
  • each phosphorylated NKIR ITIM mainly binds to the same PTP1C-SH2 domain, and do not support the potentiation of PTPase activity due to the double SH2 occupancy. Irrespective of the effect of phosphorylated NKIR on PTPase function, it is also possible that the recruited PTPases act as docking molecules for recruiting and/or activating in turn other effector/adaptor molecules, as has been shown for PTPID (Li, et al. 1994. Mol. Cell. Biol. 14:509).
  • NKIR NK receptor lectins
  • human NKIR contain Ig-like domains, both receptors bind MHC class I, and transduce inhibition of NK and T cell activation programs upon engagement.
  • Our data show that despite their major structural difference, human and mouse NKIR recruit, upon intracytoplasmic tyrosine phosphorylation, the SH2-tandem PTPases PTPIC and PTPID.
  • mouse lectin NKIR and human Ig-like NKIR suggests that both types of receptors share common transduction pathways, and document a striking convergent evolution for the recognition of MHC class I by T and NK lymphocytes, illustrating the importance of MHC class I quality control.
  • Example 10 This example illustrates that negative FC ⁇ RIIBl signaling is mediated by inhibition of CD 19 tyrosine phosphorylation and association with PI 3-kinase
  • the B-cell receptor for IgG is a potent transducer of negative signals which block B cell activation and the immune response.
  • Co-ligation of FcgRIIBl and B lymphocyte antigen receptor (BCR) causes premature termination of phosphoinositide hydrolysis and Ca ⁇ "1" mobilization, blocking BCR mediated proliferative responses.
  • BCR B lymphocyte antigen receptor
  • Previous studies have revealed that this inhibitory signal is mediated by phosphorylation of FcgRIIBl Ty r 309, which recruits and activates the protein tyrosine phosphatase PTPIC.
  • the target(s) of PTPIC is unknown.
  • FcgRIIBl inhibition of BCR signalling is mediated by dephosphorylation of CD19, a BCR coreceptor.
  • Dephosphorylation of CD 19 leads to diminished association of CD 19 with PI-3 kinase and subsequent failed BCR mediated Ca 2"1" mobilization.
  • the results define a molecular mechanism by which FcgRIIB co-engagement with BCR inhibits humoral immune responses.
  • CD 19 phosphorylation at tyrosine residues 484 and/or 515 initiates recruitment and activation of PI-3 kinase, and phosphorylation of tyrosine 393 may recruit the multifunctional oncoprotein VAV (D. A. Tuveson, et al. Science 260, 986-989 (1993)).
  • MHC class II and B7.2 CD86 that function in T-cell/B-cell collaboration, as well as in apoptosis, proliferation, and differentiation.
  • FcgRIIBl IgG immunoglobulin constant region
  • Antibodies used in this study are all rabbit polyclonals.
  • the immunogens for CD 19 and Iga were the complete cytoplasmic domains, lyn (residues 1-131 ), Syk (linker region as described [C. G. Couture, et al., Mol. Cell Biol.13, 5249 (1994)]), p85 (N-terminal SH3 domain).
  • Anti- VAV was from Santa Cruz Biotechnology, Inc., anti-p85 from Upstate Biotechnology, Inc. (used for western blotting), and anti-phosphotyrosine (Ab-2) from Oncogene Science.
  • affinity purified antibodies (except for anti- syk) were coupled to CNBr-Sepharose at 1 mg/ml, and 20 ⁇ g.
  • Syk immunoprecipitations were accomplished using 20 ⁇ l crude serum and 10 ⁇ l protein-A Sepharose (Pharmacia).
  • Western blotting was accomplished with a 1 : 1000 dilution of primary antibody, and peroxidase-conjugated protein A (Amersham) or rat anti-mouse IgGl (Zymed) for phosphotyrosine.
  • the human CD 19 cDNA was isolated from pMT2 (gift of Thomas
  • SDS was added to the cleared lysates (0.5% final), which were then boiled 5 minutes and diluted 1 to 5 in lysis buffer. Lysates were then incubated 15 minutes with antibodies to the signalling molecules indicated, washed rapidly 3x in lysis buffer, then eluted with SDS reducing sample buffer, fractionated by SDS-PAGE, and transferred to immobilon-P membranes (Millipore). The membranes were blocked with 5% bovine serum albumin, immunoblotted sequentially with anti-phosphotyrosine and anti-effector antibodies, and developed with an enhanced chemiluminescence (ECL) detection system (Amersham).
  • ECL enhanced chemiluminescence
  • A20 and IIA1.6 (an FcgRIIBl negative variant of A20) B lymphoma cells were cultured without stimulus or were stimulated with intact or F(ab')2 fragments of rabbit antibody to mouse immunoglobulin. After sequential immunoblotting for phosphotyrosine and effector, the images were scanned, and the pixel density of the anti-phosphotyrosine signal and anti-effector signal determined. The values were normalized for amount of effector present.
  • A20 cells were cultured without stimulus or were stimulated with intact or F(ab')2 rabbit anti-mouse Ig antibody for 2 min. The cells were lysed and CD 19 or p85 immunoprecipitated as described. The immunoprecipitates were washed, eluted with SDS reducing sample buffer, fractionated by SDS-PAGE on a 10% gel, and transferred to immobilon-P membranes. The membranes were sequentially immunoblotted with anti- CD ⁇ , and anti-p85 as above. The coprecipitation of PI 3-kinase activity with CD 19 was assessed from A20 cells that were stimulated and lysed as above.
  • Immunoprecipitates were washed, assayed for PI 3-kinase activity using PI as the substrate, and reaction products resolved by thin-layer chromatography.
  • the inco ⁇ oration of ⁇ 2 PO4 into phosphatidylinositol phosphate (PIP) was quantitated using a Phosphorimager.
  • Applicant compared substrate tyrosine phosphorylation following crosslinking of BCR alone and cocrosslinking FcgRIIBl with BCR.
  • the FcgRIIBl positive murine B lymphoma cell line A20 and its FcgRIIBl negative variant IIA1.6 were stimulated with either intact (I) or F(ab')2 rabbit anti-mouse immunoglobulin, and the spectra of proteins phosphorylated on tyrosine compared by anti-phosphotyrosine immunoblotting of whole cell lysates.
  • CD 19 may be a substrate for PTPIC.
  • CD 19 is prematurely dephosphorylated upon FcgRIIBl coligation with BCR.
  • substrates analyzed, including CD 19, Iga, VAV, Lyn and Syk CD 19 was phosphorylated most rapidly upon BCR ligation and was immediately dephosphorylated upon FcgRIIBl coligation.
  • CD 19 exhibited significantly reduced levels of tyrosine phosphorylation (73%) even at the earliest time point tested (15 sec). Reduced tyrosine phosphorylation of Iga was apparent only at 45 seconds and decreased to background levels by 120 seconds.
  • the immunoprecipitates were fractionated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to PVDF membrane and blotted sequentially with anti-CD19 and anti-p85.
  • SDS-PAGE SDS-polyacrylamide gel electrophoresis
  • levels of p85 associated with CD 19 remained near basal levels when cells were stimulated with intact antibody that cocrosslinked FcgRIIBl and BCR. This increased association was demonstrable by precipitation with either anti-CD 19 or anti-p85.
  • FcgRIIBl coligation with BCR caused CD 19 dephosphorylation preventing its recruitment of p85 detectable based on immunoblotting.
  • PI 3-kinase assays were performed on CD 19 immunoprecipitates from unstimulated A20 cells, or A20 cells stimulated with either F(ab')2 or intact rabbit anti-mouse Ig.
  • CD 19 isolated from unstimulated cells contained levels of PI 3-kinase activity that were only slightly above the background of the assay.
  • BCR stimulation F(ab')2
  • the amount of PI 3- kinase activity associated with CD19 was increased more than 19-fold.
  • Wortmannin inhibited both immediate and prolonged Ca 2 + responses. This may reflect the time lag imposed by the necessity to recruit and activate FcgRIIBl and PTPIC to achieve negative signalling upon FcgRIIBl -BCR coligation.
  • the above results are consistent with a critical role for CD 19 phosphorylation and PI 3-kinase translocation in BCR mediated Ca 2+ mobilization and its disruption by FcgRIIB 1 coligation.
  • BCR mediated Ca 2+ mobilization was analyzed in a plasmacytoma cell line (J558L ⁇ m3CD45+) that expresses an exogenous B cell antigen receptor and CD45, but no CD 19 as judged by immunoblotting.
  • Human CD 19+ variants of this cell were produced by retroviral transformation ( Figure 3). Ligation of the BCR in the CD19" cell line resulted in Ca 2+ mobilization, but only an initial flux was observed. In contrast, when CD 19 was expressed, initial and prolonged Ca 2+ mobilization was observed, reminiscent of normal B cells and A20 cells. Therefore, as observed when FcgRIIBl is coligated to BCR, lack of CD 19 function results in a loss of prolonged Ca 2+ mobilization.
  • CD 19 may enhance sensitivity to antigen by enhancing activation of PI 3-kinase and other effectors.
  • Fc ⁇ RIIB1 negative mutants of A20 B cell lymphoma cells were reconstituted with Fc ⁇ RIIB 1 which had been subjected to alanine scanning mutagenesis using standard techniques (Cunningham and Wells (1989) Science 244:1081-1085).
  • Cells expressing Fc ⁇ RIIBl with alanine substitutions at various sites were assayed for their ability to inhibit B cell activation following co-ligation of the receptors with the BCR was assessed.
  • B cell activation was assessed by measuring changes in intracellular Ca 2+ after stimulation of cells with antibody. Cells were loaded with Indo 1AM as described in the previous examples.
  • Example 12 This example shows that the IgE mediated activation of bone marrow derived basophils is inhibited by FcgR signaling.
  • Murine bone marrow derived mast cells were harvested from mouse femurs using standard techniques. Cells were cultured in vitro with IL-3 and c-kit ligand to enrich for the presence of mast cells. The resulting cells were greater than 95% mast cells based on Fc ⁇ R expression and functional criteria (release of seratonin upon stimulation). These bone marrow mast cells expressed both Fc ⁇ RII and Fc ⁇ R. Cells were loaded with Indo IA as described in the previous Examples. Cells were next incubated with monovalent IgE antibody to occupy surface Ig ⁇ R without activating the cells. Cells were next incubated with control or F(ab')2 fragments of rabbit anti-mouse Ig, which recognizes both IgG and IgE.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La présente invention concerne un nouveau produit et un nouveau procédé pour réguler une fonction des cellules hématopoïétiques, ainsi qu'un nouveau produit et un nouveau procédé pour identifier des composés capables de réguler les inflammations. La présente invention concerne un procédé destiné à réguler une fonction des cellules hématopoïétiques consistant à mettre une cellule en contact avec un réactif régulateur capable de modifier l'activité d'une molécule telle que PTP1C, PTPID, ITIM-p160 et ITIM-p70. La présente invention concerne également des réactifs régulateurs capables de réguler l'activité de PTP1C, PTP1D, ITIM-p160 et ITIM-p70, y compris des molécules d'acide nucléique présentant des séquences qui codent ces réactifs et des anticorps dirigés contre ces réactifs. La présente invention concerne également une composition thérapeutique contenant ces réactifs et son utilisation pour protéger des animaux contre les inflammations.
EP96909494A 1995-02-28 1996-02-28 Composes de peptidyl comprenant un motif structural itim regulant la fonction hematopoietique et leur utilisation Withdrawn EP0812330A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39762895A 1995-02-28 1995-02-28
US397628 1995-02-28
PCT/US1996/002289 WO1996026961A2 (fr) 1995-02-28 1996-02-28 Composes de peptidyl comprenant un motif structural itim regulant la fonction hematopoietique et leur utilisation

Publications (1)

Publication Number Publication Date
EP0812330A2 true EP0812330A2 (fr) 1997-12-17

Family

ID=23571989

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96909494A Withdrawn EP0812330A2 (fr) 1995-02-28 1996-02-28 Composes de peptidyl comprenant un motif structural itim regulant la fonction hematopoietique et leur utilisation

Country Status (5)

Country Link
EP (1) EP0812330A2 (fr)
JP (1) JPH11501622A (fr)
AU (1) AU5296796A (fr)
CA (1) CA2247207A1 (fr)
WO (1) WO1996026961A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09512704A (ja) * 1994-03-17 1997-12-22 ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン シグナル変換経路を調節するための産物および方法
EP0861891A1 (fr) * 1996-12-31 1998-09-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Produits pour moduler des régulations de cellules négatives et leurs applications biologiques
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
PT1003861E (pt) * 1997-08-01 2007-01-31 Schering Corp Proteínas de membrana de células de mamíferos;reagentes relacionados
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
US6355786B1 (en) 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
ATE432083T1 (de) * 1999-02-25 2009-06-15 Nat Jewish Ct For Immunology A Produkt und methode zur behandlung von konditionen assoziiert mit rezeptor- desensibilisierung
AU2001247543A1 (en) * 2001-03-16 2003-09-02 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy of allergies
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2007122815A1 (fr) * 2006-04-14 2007-11-01 Ono Pharmaceutical Co., Ltd. Anticorps bivalents diriges contre bir1
KR101258456B1 (ko) 2011-01-13 2013-04-26 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 비만세포 탈과립 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340012C (fr) * 1987-08-17 1998-08-25 Trustees Of Leland Stanford Jr. University Determinant peptidique associe a l'immunite
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
WO1994025570A1 (fr) * 1993-04-23 1994-11-10 Sloan-Kettering Institute For Cancer Research Procede de criblage permettant de detecter des cibles d'agents anti-inflammatoires et antiallergiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9626961A2 *

Also Published As

Publication number Publication date
JPH11501622A (ja) 1999-02-09
AU5296796A (en) 1996-09-18
CA2247207A1 (fr) 1996-09-06
WO1996026961A3 (fr) 1997-04-10
WO1996026961A2 (fr) 1996-09-06

Similar Documents

Publication Publication Date Title
Holland et al. Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands
US6638764B2 (en) Methods of inhibiting phagocytosis
AU743490B2 (en) NTN-2 member of TNF ligand family
AU7608898A (en) Ntn-2 member of tnf ligand family
AU741419B2 (en) Ligand for herpes simplex virus entry mediator and methods of use
US20070218070A1 (en) Methods of modulation of the immune system
AU8767698A (en) Novel orphan receptor
WO1996026961A2 (fr) Composes de peptidyl comprenant un motif structural itim regulant la fonction hematopoietique et leur utilisation
KR100262420B1 (ko) 바이러스, 특히 레트로바이러스의 복제를 억제하기 위한 "면역결핍-바이러스 억제 림포카인(아이에스엘)"의 용도
CA2318727A1 (fr) Molecules d'acide nucleique et proteine spoil, et utilisations
US6998108B1 (en) Antibodies to p30 polypeptides and methods making and using same
WO1999026980A1 (fr) Reactifs et procedes d'utilisation de proteines de la famille sap, nouveaux regulateurs de transduction de signaux
EP1021537A1 (fr) Molecules associees au recepteur des lymphocytes t (tram) et leur mode d'utilisation
US8084217B2 (en) CD161 ligand, pilar, for modulating activation and proliferation of T cells
CA2399391A1 (fr) Molecules trade et utilisations associees a ces dernieres
EP1027436A1 (fr) Adn et polypeptides recepteurs des proteines de semaphorine a codage viral
EP0745123A1 (fr) pp32: PROTEINE ASSOCIEE A CD45 RECEMMENT IDENTIFIEE
US6268130B1 (en) RP compositions and diagnostic uses therefor
AU748168B2 (en) Viral encoded semaphorin protein receptor DNA and polypeptides
US6562949B1 (en) Antibodies to viral encoded semaphorin protein receptor polypeptides
US20030166502A1 (en) Differential regulation of T cell survival and proliferation
Turner Signal transduction by the high affinity receptor for immunoglobulin E, FcϵRI, in the mast cell line RBL-2H3

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970929

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990901